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ABSTRACT	
 
Multiple Sclerosis (MS) is a chronic immune-mediated disease in which the immune system 
directs an abnormal response against myelin, an insulating lipidic structure produced by 
oligodendrocytes responsible of fast axonal electric transmission. During MS, demyelination 
disrupts neuronal conductance, leading to motor symptoms, and impairs oligodendroglial 
functions. Under these conditions, oligodendrocyte precursor cells (OPCs) are recruited at 
the injury site to re-myelinate damaged axons, but this process is often defective.  
Many disease-modifying treatments (DMTs) are available but there are several unmet 
needs: delaying disease progression, providing neuroprotection and promoting re-
myelination. 
The aim of this thesis was to characterize GPR17 alterations both in murine MS models and 
in human MS lesions, to assess whether this receptor, a key actor of oligodendrogenesis, 
can be proposed as a pharmacological target in re-myelinating strategies. 
GPR17 is a G protein-coupled receptor activated by both uracil nucleotides and cysteinyl-
leukotrienes, mediators involved in inflammatory responses in the CNS. Under physiological 
conditions, GPR17 is expressed in OPCs, with maximal levels in immature oligodendrocytes 
and progressive downregulated in terminally differentiating cells. A marked GPR17 up-
regulation was found in rodent models of cerebral trauma, ischemia and in lysolecithin-
induced focal demyelination; suggesting that GPR17 takes part in the pathological 
mechanisms of demyelination either as a consequence of the disease or contributing to the 
lesion. In mice with Experimental Autoimmune Encephalomyelitis (EAE), we observed a 
marked and persistent upregulation of GPR17 in the OPCs accumulating at demyelinating 
lesions. Conversely, no GPR17 upregulation was found in a model characterized by a much 
lower degree of inflammation, i.e. cuprizone-induced demyelination. In a similar way to 
EAE, in autoptic samples from MS patients, many GPR17-positive activated cells 
accumulated at the border of active lesions. Furthermore, we demonstrated that the 
chemokine CXCL12 can also directly act as a promiscuous activator of GPR17, corroborating 
our hypothesis of a common pathophysiological role for GPR17 and chemokine receptors in 
leading the re-myelination processes.	Characterizing the molecular defects of GPR17 in MS 
will help re-establishing its correct function in re-myelination and foster the identification 
of new pharmacological strategies to enhance OPCs reparative potential in MS. 
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RIASSUNTO	
 
La sclerosi multipla (SM) è una patologia cronica mediata dal sistema immunitario il quale 
dirige una risposta anticorpale aberrante contro la mielina, la struttura lipidica prodotta 
dagli oligodendrociti (OL) che isola gli assoni favorendo la rapida trasmissione degli impulsi 
nervosi. Nella SM, in seguito alla demielinizzazione si verifica un’interruzione della 
comunicazione neuronale che porta a disabilità motorie e compromette le funzioni degli 
oligodendrociti. In queste condizioni, i precursori degli OL (OPC) vengono reclutati al sito di 
danno per rimielinizzare gli assoni danneggiati ma questo tentativo di riparo spesso non 
viene completato con successo.   
Attualmente sono disponibili diverse terapie a base di farmaci in grado di modificare la 
malattia (DMT) ma rimangono dei bisogni clinici insoddisfatti: ritardare la progressione 
della malattia, fornire neuroprotezione e promuovere la rimielinizzazione. 
Lo scopo di questa tesi è stato caratterizzare le alterazioni del recettore GPR17 sia in un 
modello murino di SM, sia nelle lesioni umane, per verificare se questo recettore, che ha un 
ruolo chiave nel differenziamento degli OL, possa essere proposto come bersaglio 
farmacologico per strategie terapeutiche rimielinizzanti. 
GPR17 è un recettore accoppiato a proteina G che può essere attivato da diversi mediatori 
delle risposte infiammatorie nel sistema nervoso centrale quali ad esempio i leucotrieni 
cisteinici e i nucleotidi. In condizioni fisiologiche, GPR17 è espresso dagli OPC, 
raggiungendo livelli massimi di espressione allo stadio di OL immaturi e progressivamente 
spento durante la maturazione terminale. In modelli murini di trauma cerebrale, ischemia e 
demielinizzazione focale indotta con lisolecitina è stato riscontrato un marcato aumento 
dei livelli di GPR17 suggerendo che questo recettore è implicato nei meccanismi patologici 
di demielinizzazione e rimielinizzazione. In topi con encefalite sperimentale autoimmune 
(EAE), abbiamo osservato un marcato e persistente aumento di OPC esprimenti GPR17 nei 
siti di lesioni demielinizzanti. Al contrario, nessun aumento di GPR17 è stato riscontrato in 
un modello caratterizzato da una diversa tipologia di risposta infiammatoria quale il 
modello di demielinizzazione indotta da cuprizone. In un modo simile a quanto descritto nel 
modello di EAE, in campioni autoptici di pazienti umani con SM, abbiamo osservato la 
presenza di cellule GPR17-positive accumulate ai bordi delle lesioni attive. Inoltre, abbiamo 
dimostrato che anche la chemochina CXCL12 può attivare GPR17, confermando la nostra 
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ipotesi di un ruolo fisiopatologico comune per GPR17 e i recettori per le chemochine nel 
guidare i processi di rimielinizzazione. La caratterizzazione delle alterazioni di GPR17 in SM 
è quindi importante per ripristinarne le funzioni e promuovere la rimielinizzazione 
attraverso l’identificazione di nuove strategie farmacologiche volte a incrementare il 
potenziale riparativo endogeno degli OPC in corso di SM. 
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Chapter	1		
Multiple	Sclerosis		
	
1.1	Multiple	sclerosis:	clinical	features	
	
1.1.1	Definition		
Multiple sclerosis (MS) is a human inflammatory demyelinating disease of the central 
nervous system (CNS) and the most common non-traumatic cause of neurological disability 
in young people in the western world (Coclitu et al., 2016). 
MS is characterized by the development of multiple and diffuse foci (sclerosis) of 
demyelination in the brain and spinal cord as a result of an inflammatory process ongoing. 
Indeed, MS is a putatively autoimmune disease where inflammation is the cause for 
demyelination, axonal damage and neuronal loss but the exact antigen remains unknown, 
so for this reason MS is considered to be "immune-mediated" rather than "autoimmune". As 
in other chronic inflammatory diseases, the CNS of patients with MS shows infiltration of 
activated T cells and macrophages, dendritic cells, B cells and plasmacells. This implies 
potential roles for both cellular and humoral immune responses and the engagement of 
different immunopathological effector mechanisms in CNS tissue damage. (Coclitu et al., 
2016; Peru et al., 2008; Keegan and Noseworthy, 2001). 
1.1.2	Symptoms	and	diagnosis		
	
MS symptoms are variable and unpredictable. Typical clinical signs include temporary loss 
of vision, sensory and motor problems but also fatigue, neurocognitive changes, and 
impairment of bladder-, bowel- and sexual functions (Keegan and Noseworthy, 2001). 
Initially, most patients show subacutely “attacks” or “relapses” of neurological dysfunction 
over hours to days, then plateau and improve (sometimes incompletely) over days to 
weeks, either spontaneously or with corticosteroid treatment. The neurological symptoms 
reflect the location of the lesion within the CNS; for example, visual loss reflects a lesion of 
the optic nerve; hemi-, para-, or quadriparesis, with or without bowel/bladder dysfunction, 
reflects a lesion of the spinal cord; vertigo or diplopia, a lesion of the brain stem; and 
ataxia, a lesion of the cerebellum. However, many lesions are clinically silent. Other 
symptoms, such as debilitating fatigue, paresthesias on neck flexion (Lhermitte’s 
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symptom), and heat-exacerbated symptomatic worsening (e.g., Uhthoff’s symptom), may 
be present. Occasionally, severe attacks occur with multifocal neurological involvement. 
Although MS is common, other causes for this symptom complex must be considered 
(Keegan and Noseworthy, 2001). Other conditions can damage myelin in the CNS, including 
viral infections, side effects from high exposure to certain toxic materials, severe vitamin 
B12 deficiency, autoimmune conditions that lead to inflammation of blood vessels (the 
"collagen-vascular diseases"), and some rare hereditary disorders (e.g., metachromatic 
leukodystrophy, - Poeppel et al. 2005). Demyelination of the peripheral nervous system 
(PNS) occurs also in Guillain-Barré Syndrome (Jasti et al., 2016).  
Although it is facilitated by supportive laboratory and radiological investigations, MS 
continues to be diagnosed on a clinical basis. Careful and repetitive examinations may be 
needed to establish an exact diagnosis among the possible causes of neurologic symptoms. 
At this time, there are no symptoms, physical findings or laboratory tests that can 
univocally determine if a person has MS. Several strategies are used to determine if a 
person meets the long-established criteria for a diagnosis of MS, and to exclude other 
possible causes of symptoms that person is experiencing. These strategies include a careful 
medical history, a neurologic exam and various tests including magnetic resonance imaging 
(MRI), evoked potentials (EP) and spinal fluid analysis (McDonald WI, et al., 2001; Hessen C. 
et al., 2009). 
The McDonald criteria for diagnosing MS were published in 2001 by a team led by Prof Ian 
McDonald, and were revised in 2005 and 2010. McDonald's criteria are the standard clinical 
case definition for MS and the 2010 version is regarded as the gold standard test for MS 
diagnosis. 
The criteria specify that, in order to make a diagnosis of MS, the physician must: 
- Find evidence of damage in at least two separate areas of the CNS, which includes 
the brain, spinal cord and optic nerves AND 
- Find evidence that the damage occurred at least one month apart AND 
- exclude all other possible diagnoses 
The Revised McDonald Criteria, published by the International Panel on the Diagnosis of 
Multiple Sclerosis (Polman et.al, 2011), include specific guidelines for using MRI, visual 
evoked potentials (VEP) and cerebrospinal fluid analysis to speed the diagnostic process 
(Fig.1.1). These tests can be used to look for a second area of damage in a person who has 
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experienced only one attack (also called a relapse or an exacerbation) of MS-like symptoms 
— referred to as clinically-isolated syndrome (CIS).  
	
Figure	1.1	-	The	2010	McDonald	Criteria	for	Diagnosis	of	MS	(modified	from	Polman	et	al.,	2011)	
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Furthermore, the use of brain MRI for evaluation of neurological disorders has increased in 
the past two decades, leading to an increased detection of incidental findings on brain MRI. 
The most common of these asymptomatic abnormalities are white matter lesions that are 
interpreted as demyelinating based on radiological criteria. However, in the absence of 
associated clinical symptoms suggestive of MS, a definite diagnosis cannot be made in 
patients with these incidental white matter lesions that are now diagnosed as radiologically 
isolated syndrome (RIS). 
	
1.1.3	Clinical	courses	
Current diagnostic categories provide a clinical description of the disease course of MS. 
People with MS typically experience one of four disease courses (see table 1.1), which can 
be mild, moderate or severe and that will be described in this paragraph. But there are 
some exceptions represented by CIS, that may evolve in MS, and by the RIS, due to the easy 
and wide availability of brain MRI in the past two decades that has led to its increasing use 
in evaluation of a variety of neurological symptoms. 
In most patients (85%), MS initially has a relapsing-remitting course (RRMS) which is 
characterized by discrete clinical “attacks” or “relapses” followed by periods of remission. 
RRMS is the most typical presentation in younger patients.  
Many years after onset, in the majority of RRMS patients the relapsing course will be 
followed by a secondary progressive phase (SPMS). These patients will develop a slow, 
insidiously progressive, neurological deterioration over many years with or without clinical 
attacks superimposed.  
A minority of patients (∼15%) have primary progressive MS (PPMS) characterized by a 
progressive course from onset, an absence of clinically evident relapses, and less 
conspicuous inflammation on MRI. Progressive relapsing MS (PRMS) involves a progressive 
course from onset with occasional relapses later in the disease. This category may be of 
less prognostic significance, however, as occasional relapses occurring in the context of a 
predominantly progressive course do not appear to significantly alter long-term outcome 
(Compston et al., 2008). 
Clinically isolated syndrome 
CIS is now considered one of the MS disease courses. CIS refers to a first episode of 
neurologic symptoms that lasts at least 24 hours and is caused by inflammation or 
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demyelination in the CNS. Based upon clinical symptoms alone, CIS and MS may appear the 
same: like MS, CIS is two to three times more common in women than men; 70% of people 
diagnosed with CIS are between the ages of 20 and 40 years; a person with CIS has 
experienced more than one episode and may or may not evolve to MS. According to the 
2010 revisions to the diagnostic criteria for MS, when CIS is accompanied by specific 
findings on MRI that demonstrate that another episode has occurred in the past, the 
diagnosis of MS can be made. 
According to the 2010 revisions to the diagnostic criteria for MS, when CIS is accompanied 
by specific findings on MRI that demonstrate that another episode has occurred in the past, 
the diagnosis of MS can be made (Polman et al., 2011). 
	
Table	1.1	-	Main	clinical	courses	of	multiple	sclerosis	 
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Radiologically isolated syndrome  
Given to the widespread use of MRI, diagnosis of RIS often occurs during diagnosis of 
another unrelated condition (e.g. head trauma or migraine headache). The most common of 
these incidental abnormalities are white matter lesions that based on their appearance, 
location, and distribution are consistent with demyelination but are not associated with any 
clinical symptoms suggestive of MS. For this reason, the term radiologically isolated 
syndrome (RIS) has been proposed to describe this entity for the first time by Okuda in 2009 
(Okuda et al., 2009). 
The clinical significance and prognostic implication of subclinical lesions in patients with 
RIS remains controversial. There is some evidence suggesting that one-third of patients with 
RIS have an increased risk of developing MS in five years, implying that RIS, in some cases, 
constitutes a preclinical stage or subclinical form of MS. These results suggest that the 
McDonald criteria lack some degree of sensitivity in detecting MS in its earliest phases. 
Another issue relates to the treatment recommendations for patients with RIS (Leahy and 
Garg, 2013), but it will be discussed later. 
	
1.2	Epidemiology	and	pathogenesis	
The precise etiology of MS remains unknown. It likely results from complex interactions 
between environmental and genetic factors, which lead to an aberrant immune response 
and damage to the myelin sheath, oligodendrocytes, axons, and neurons. A number of 
factors appear to influence the risk of MS.  
1.2.1	Prevalence	and	incidence		
MS affects approximately 400,000 people in the United States (Evans et al., 2013) and 2.5 
million worldwide. Europe is considered a high prevalence region for MS, containing more 
than half of the global population of people diagnosed with MS reported by the World 
Health Organization in 2008. MS typically begins between the ages of 20 and 40 years and it 
is the leading cause of non-traumatic disability in young adults. Initial symptoms rarely 
occur before age 10 years or after age 60 years. It is also clear that populations vary in 
their susceptibility to MS with a gender difference: women are affected approximately 
twice as often as men, except in individuals with the primary-progressive form of the 
disease, where there is no gender preponderance. 
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Thus, factors which influence MS incidence include population genetics, the interplay 
between genes and a geographically determined physical environment, and socioeconomic 
structure, including availability of medical facilities (Howard et al., 2016). 
In the last years, many studies shed light on these components of MS and they are 
presented in the next paragraphs. 
Geography and environmental risk factors 
The prevalence rates of MS have been reported to vary by continent and geographical 
latitude. The condition is of high prevalence (>30 per 100,000) in northern parts of Europe 
and North America; medium prevalence (5-30 per 100,000) in southern Europe and southern 
United States; and Central and South America (10-20 per 100,000); and low prevalence (<5 
per 100,000) in Asia and South America.  
Koch-Henriksen and Sørensen conducted an extensive literature search and meta-regression 
analysis to evaluate the changes in MS incidence and prevalence worldwide. Their analysis 
indicated that the prevalence and incidence of MS are increasing over time. The increase in 
prevalence was presumed to be due to prolonged survival of patients with MS, while the 
increase in incidence was thought to be due to a number of factors. In particular, the ratio 
of disease in women to men has increased over time from less than 1.5 to greater than 2. 
This increase in MS among females appears to be driving the increase in incidence, and may 
be due to changes over time in occupation, cigarette smoking, obesity, birth control, and 
later childbirth. Furthermore, the previously proposed latitude-related differences in 
prevalence were dispelled in the northern hemisphere but supported in the southern 
hemisphere. MS is fairly common in Caucasians of northern European ancestry, but less 
common where non-Caucasians live, in low-income countries, and in tropical zones (Koch-
Henriksen and Sørensen, 2010).  
Other environmental factors which may relate to MS are sunlight and ultraviolet radiation 
exposure, vitamin D, Epstein-Barr virus (EBV) and other viruses, and other infective agents. 
The hypothesis that higher exposure to sunlight, and consequently ultraviolet radiation, is 
associated with a lower incidence of MS tends to conveniently fit with the latitude-based 
observations; however, exceptions exist. Israeli-born individuals of African descent have 
higher MS rates than their immigrant predecessors, although it is unlikely that their 
exposure to sunlight was different. For the same reasons, the relationship between vitamin 
D and MS is unclear. Although epidemiologic studies correlated increased vitamin D intake 
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with decreased MS incidence, exceptions among Israeli-born individuals do not support the 
association (Milo and Kahana 2010).  
Genetics 
Familial aggregation in MS has not been compelling. Evidence for a genetic predisposition 
includes a 20- to 40-fold increased risk of MS in first-degree relatives of patients with MS 
and a 25% to 30% concordance in monozygotic twins, compared with only 5% in dizygotic 
twins. However, monozygotic twins of afflicted individuals had a 30% risk of the disease, 
with a similar rate in dizygotic twins to other siblings (Ebers et al., 1986), demonstrating 
that environmental factors and other unknown influences most likely contribute to disease 
susceptibility. 
Bashinskaya and colleagues provided an excellent review of genome-wide association 
studies (GWAS) in MS. The strongest known genetic factor affecting MS susceptibility is the 
HLA-DRB1*1501 haplotype. Because it is well known that the HLA locus is an essential 
component directing the immune response and immune developments, it is not surprising 
that the major histocompatibility complex (MHC) region still represents about one-half of 
the MS genetic risk. 
However, it is not essential for the development of MS, as it only increases the risk by 2- to 
4-fold and is present in approximately 20% to 30% of healthy individuals. Non-HLA genes 
associated with MS are associated with T-cell function and may indicate the leading role of 
T-cell immunity in MS development (Bashinskaya et al., 2015).  
Exposure to infectious agents 
Viral and other infectious exposures may predispose a host to an autoimmune attack.  
Exposure to EBV at an early age in children has been linked to reduced incidence of MS, 
while exposure in the form of infectious mononucleosis later in life (late adolescence) is 
linked to an increased risk. EBV prevalence also appears to correlate with the observed 
differences in MS based on latitude and socioeconomic structure (Tzartos et al., 2012). It 
has also been postulated that the lower rate of herpes simplex virus (HSV) in patients with 
MS may suggest a protective effect of HSV, or an immunomodulatory effect on the outcome 
of EBV. Exposure to certain bacteria (i.e., Acinetobacter species, Chlamydia pneumonia, 
Pseudomonas aeruginosa), mycobacteria, or helminthes has also been linked to MS, 
although the data are not strongly associated (Tullman, 2013).  
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1.2.2	Immunopathophysiology		
The primary trigger of immune response in MS is unknown but it is believed that early in the 
inflammatory cascade, a response is triggered against myelin antigens, such as myelin basic 
protein (MBP), proteolipid protein (PLP), myelin/oligodendrocyte glycoprotein, MAG, and 
gangliosides. 
Studies in experimental allergic encephalomyelitis (EAE), histopathological studies of MS 
lesions, and immunologic markers in serum and cerebrospinal fluid of MS patients suggest 
that MS is an immune-mediated disease. A virus, bacterium, or other environmental toxin 
might induce an immune response in genetically susceptible persons (Frohman et al., 2006; 
Prineas and Parratt, 2012). Antigen-presenting cells (APCs) provide relevant antigens to 
CD4+ T helper cells in the periphery, which lead to their activation and the subsequent 
generation of autoreactive pro-inflammatory T helper (Th) 1 and 17 subsets (Frohman et 
al., 2006). B-cells and monocytes are also activated. These autoreactive T-cells interact 
with adhesion molecules on the endothelial surface of CNS vessels and, with antibodies and 
monocytes, cross the disrupted blood-brain barrier with the aid of proteases (e.g., matrix 
metalloproteinases) and chemokines. Within the CNS, target antigens are recognized 
(putative antigens include myelin basic protein, myelin-associated glycoprotein, myelin-
oligodendrocyte glycoprotein, proteolipid protein, alpha B-crystallin, phosphodiesterases, 
and S-100 protein), T-cells are reactivated, and the immune response is amplified. Pro-
inflammatory Th cells proliferate and B cells continue their maturation to antibody-
secreting plasma cells, while monocytes become activated macrophages (Wuest et al., 
2011). Together, these immune cells produce inflammatory cytokines (e.g., IL-12, IL-23, 
interferon g, tumor necrosis factor a), proteases, free radicals, antibodies, nitric oxide, 
glutamate, and other stressors that collectively lead to damage of myelin and 
oligodendrocytes. In the appropriate cytokine milieu, CD4+ Th2 cells proliferate and 
secrete anti-inflammatory cytokines (e.g. IL-4, Il-5, IL-13) and transforming growth factor b 
(TGFb) that suppress the immune response. Depending on the location and extent of 
damage, demyelination may impair or block nerve conduction and result in neurologic 
symptoms (Bielekova et al., 2006; Kaur et al., 2012; Bielekova et al., 2000). With a loss of 
trophic support from oligodendrocytes, axons may degenerate to cause irreversible 
neurological deficits. Spontaneous improvement of symptoms is attributed to resolution of 
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inflammation, adaptive mechanisms (e.g. reorganization of sodium channels), or 
remyelination. 
It had long been thought that Th1 and Th2 subsets arose from the terminal differentiation 
of the CD4+ T cells. However, a third pathway has been identified, induced by IL-1, IL-6, 
and TGFβ, and then expanded and maintained by IL-23, which is secreted by APCs. This 
third subset, a pro-inflammatory T helper cell, is known as Th17 (because it produces IL-
17). Th17 cells secrete a number of cytokines, including TNFa and GM-CSF, which are 
critical for the development of EAE. Patients with MS have monocyte-derived dendritic cells 
that secrete higher levels of IL-23 than healthy people. Higher levels of IL-17 mRNA-bearing 
mononuclear cells are found in the serum of patients with MS experiencing relapses than in 
those with MS in remission (Frohman et al., 2006; Wegner et al., 2010; Matusevicius et al., 
1999).  
Although MS is typically considered a T cell–mediated disease, a growing number of 
evidence supports a pathogenic role of B cells, including the frequent observation of 
intrathecal production of immunoglobulin in patients with MS, identification of antibodies 
that react to specific myelin antigens within MS lesions, a pathological pattern of MS 
characterized by antibody-associated demyelination, and the discovery of B cell follicles in 
the meninges of patients with secondary-progressive MS (pathological patterns are 
described in details in paragraph 1.2.3). Furthermore, B cells are efficient antigen-
presenting cells, and B cell depletion is considered by many scientists a promising 
therapeutic approach in MS (Tullman, 2013).  
1.2.3	Pathological	heterogeneity	and	staging	of	MS	lesions	
Although plaques may occur throughout the CNS, they are most common in the optic 
nerves, cerebral periventricular white matter, brainstem, and spinal cord white-matter 
tracts. MS lesions are classified histologically as pre-active, acute, chronically active, and 
inactive (Van Der Valk and De Groot, 2000).  
Preactive lesions, characterized by discrete abnormalities of WM, such as clusters of 
microglial cells, strongly HLA-DR-and CD45-positive, and few perivascular inflammatory 
cells, but no demyelination. 
Acute MS lesions have indistinct margins, hypercellularity, intense perivascular infiltration 
by lymphocytes, parenchymal edema, loss of myelin and oligodendrocytes, widespread 
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axonal damage, plasma cells, myelin-laden macrophages, hypertrophic astrocytes, and 
little astroglial scarring. 
Chronic MS lesions have sharp edges, with a perivascular cuff of infiltrating cells, lipid-
laden and myelin-laden macrophages, hypertrophic astrocytes, some degenerating axons, 
dissolution of myelin into droplets which are phagocytized by macrophages, and 
demyelination associated with immunoglobulin deposition. In particular, chronic active 
lesion are defined with a hypocellular centre and a hypercellular rim; chronic inactive, 
defined as a hypocellular lesion. 
Chronic lesions may also exhibit an increase in oligodendrocytes and remyelination. 
Lucchinetti and colleagues identified 4 distinct pathological patterns in an 
immunohistopathological study of actively demyelinating MS lesions from 83 cases, which 
included 51 biopsies and 32 autopsies. All 4 patterns (see fig.1.2) contained an 
inflammatory infiltrate consisting of T lymphocytes and macrophages. The most common 
type, pattern II, was characterized by the deposition of immunoglobulin and complement. 
Pattern I was characterized by macrophage-associated demyelination. In patterns III and IV, 
demyelination was due to an oligodendrogliopathy. Pattern III was differentiated from 
pattern IV by a preferential loss of myelin-associated glycoprotein. The same lesion pattern 
was observed within each patient, but there was marked heterogeneity between patients, 
suggesting that MS might have multiple pathogenic mechanisms (Denic et al., 2011).  
	
Figure	1.2	–	Pathological	patterns	of	MS	lesions	(modified	from	Denic	et	al.,	2011)	
1.3	Therapy	
In MS, medications are used to modify the disease course (disease modifying therapies – 
DMTs), treat relapses and manage symptoms. Along with the other essential components of 
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comprehensive MS care, these medications help people manage their MS and enhance their 
comfort and quality of life. 
1.3.1	Approved	treatments	in	MS	
Currently available DMTs, all of which have immunomodulatory or immunosuppressive 
properties, improve the course of RRMS (see table 1.2). However, current DMTs fail to 
benefit the later, in which neurodegenerative mechanisms assume overriding clinical 
importance, and a high proportion of patients, evolving to a progressive phase, are not 
responsive to any existing therapy (Wingerchuk and Weinshenker, 2016). 
Such DMTs include injectable (interferon-beta and glatiramer acetate) and oral medications 
(fingolimod, teriflunomide, and dimethyl fumarate), monoclonal antibodies (natalizumab 
and alemtuzumab), and 1 chemotherapeutic agent (mitoxantrone). They are all indicated 
for patients with RRMS still in relapse, but, other than mitoxantrone, they do not have a 
role in the progressive phase of the illness. In patients with newly diagnosed MS and low 
disease activity, most authorities suggest starting treatment as soon as possible to influence 
the frequency of relapses, stabilize disease activity, and lessen long-term disability. The 
nonspecific immunosuppressants azathioprine and cyclophosphamide have been used 
frequently without clearly established efficacy. Cladribine, mitoxantrone, antilymphocyte 
globulins, cyclosporine, and tacrolimus are chemotherapeutic agents with use as 
semispecific suppressors of MS disease activity. In extremely severe cases, total lymphoid 
irradiation may modulate the immune system, potentially benefiting MS, though controlled 
trials are lacking. Several peptides are being explored that interfere with binding within 
the trimolecular complex (T-cell receptor, antigen, and MHC class II molecule), potentially 
leading to more specific agents decreasing the activity of the disease with minimal systemic 
immunosuppression (Vandenbark et al., 1996). 
Acute exacerbations are often initially treated with corticosteroids that enhance the 
resolution of symptoms and signs, though do not significantly affect the long-term outcome 
of an exacerbation. There are no certain dosing guidelines, although solumedrol 1g for 5 
days is an appropriate course of treatment. Pulse therapy with corticosteroids is associated 
with many temporary side effects such as insomnia, irritability, fluid retention, increased 
appetite, weight gain, hyperglycemia, hypertension, dyspepsia, depression, psychosis, bone 
fractures, and osteoporosis. In patients with poor venous access or otherwise intolerable 
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reactions to corticosteroids, adrenocorticotropic hormone may be used instead. 
Plasmapheresis is sometimes used in severe relapses that are refractory to corticosteroids. 
Therapies focused on improving conduction include 4-aminopyridine (4-AP) and 3, 4-
diaminopyridine (3, 4-DAP), both potassium channel blockers that amplify and prolong 
action potentials. Preliminary studies with 4-AP demonstrated improvement in may 
measures of neurologic function. However, when a large, multicenter, double- blind, 
placebo-controlled, study was performed, it failed to show an effect on the Expanded 
Disability Status Scale (Van Diemen et al., 1992). Unfortunately, higher levels of these 
medications can result in seizures and encephalopathy, potentially preventing sufficient 
dosage for demonstrable effect (Bever et al., 1994). 
Symptomatic therapy for MS is an important aspect of management (Schapiro, 1994). 
Paresthesia may respond to antidepressants and anticonvulsants. Anticholinergic and b-
blocker medications can improve bladder function, and fatigue can require amantadine and 
CNS stimulants. There are no medications currently available to treat muscle weakness, 
though physical therapy can optimize patient function. Spasticity, muscle cramps, and 
spasms respond to stretching and antispasticity medications, including baclofen, tizanidine, 
and benzodiazepines. If necessary, botulinum toxin can be introduced into specific muscles 
or, if generalized spasticity is refractory to other treatments, intrathecal baclofen 
administered by an implantable subcutaneous pump or dorsal root rhizotomy may be 
considered. Adaptive equipment includes ankle-foot orthoses for foot-drop dysfunction and 
canes, walkers, and wheelchairs for mobility. Tremor may respond to a variety of 
medications. Propranolol and primidone are often used initially, though isoniazid, 
buspirone, trazadone, baclofen, carbamazepine, gabapentin, benzodiazepines, and 
unilateral thalamotomy, can all be effective (Whittle and Haddow, 1995). 
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Table	1.2	-	Approved	disease	modifying	therapies	for	relapsing	multiple	sclerosis	(modified	from	Wingerchuk	et	al.,	2016)	
DMTs are often recommended for people diagnosed with a CIS that is considered more likely 
to progress to clinically definite MS (CDMS), with the goal of delaying a second attack.  
At this time, it is difficult to predict the future course a person who is diagnosed with a CIS 
will experience. Many episodes of CIS are mild and resolve without treatment. In other 
cases, treatment with high dose oral or intravenous methylprednisolone (a steroid) is 
typically recommended. Several large-scale clinical trials have been conducted to 
determine whether early treatment following a CIS can delay the second clinical event, and 
therefore the diagnosis of CDMS. Based on the results of these studies, the U.S. Food & 
Drug Administration (FDA) has expanded the indication of several medications used to treat 
MS to include individuals who have experienced a first clinical episode and have MRI 
findings consistent with MS. The results of these trials, and the FDA’s approval of expanded 
labeling for certain medications used to treat MS, support the earliest possible treatment 
for MS, which many believe may delay the development of permanent clinical disabilities. 
Although some might support use of DMTs to delay the clinical or radiological progression 
similar to CIS patients, there are no studies to suggest this might be beneficial even for RIS 
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patients at higher risk of MS. Moreover, the risk factors are not always clear, and the other 
caveat may be misdiagnosis of RIS in some cases where other conditions may mimic MS 
radiologically. Given the uncertainty about the diagnosis and management of these 
patients, only a small proportion of RIS patients get treated with disease modifying 
therapy. There is currently no set protocol for managing patients with RIS. These patients 
are usually followed with surveillance MRIs every six months to a year or on as needed basis 
depending on the patient’s wishes and the treating neurologist's preference. If clinical 
symptoms develop over time (conversion to CIS), most of these patients would be initiated 
on DMT. There is, however, a lack of evidence to support the use of DMT in RIS patients 
who show radiological progression on follow up imaging in absence of clinical progression 
(Leahy and Garg, 2013). 
1.4	Future	direction	
	
1.4.1	Personalized	medicine	for	MS	
Although drug mechanisms can occasionally be personalized for cancer on the basis of 
genomic or tissue specific DNA mutation detection and pathobiology, this approach is not 
feasible for MS. Nevertheless, optimization of treatment for MS remains a highly 
individualized process. An intermediate approach between the escalation and induction 
strategies, in which risk for future disability, comorbidities, personal preferences, and risk 
mitigation strategies are considered to select a therapy, provides the best compromise 
between efficacy and potential risk.  
The diverse efficacy and safety profiles of DMTs have resulted in greater emphasis on 
“personalized” approaches that tailor decisions about treatment to a patient’s disease 
characteristics and preferences. And, because the medicines all are relatively expensive, 
better ways of making most effective use of them are needed. However, lack of prognostic 
and therapeutic biomarkers continues to hinder development of biologically based 
strategies.  
Clarifying the monitoring strategies for adverse effects and breakthrough MS would be 
crucial. The development of radiological and biological biomarkers could allow in the future 
personalizing treatment and precision medicine in MS (Comabella et al., 2016).  
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Understanding the heterogeneity of the MS syndrome involves an active process of 
‘deconstruction’ to define the biologically distinct diseases included within it and their 
interactions with individual, patient-specific factors. Coordinated collection and sharing of 
data (not just clinical data but also that from devices and patient-reported outcomes and 
behavioural, employment and life-style data), development of predictive models and their 
progressive evaluation in the care of individual patients will be an essential part of this. 
Treating the right patient with the right drug early in the disease course, before disability 
has been acquired, could yield long term benefits (Gafson et al., 2016). 
1.4.2	Agents	in	trial	
After Fingolimod, the first oral DMT approved in 2010, many other oral agents have been 
approved too or are currently in phase III trials or are going to be submitted to the 
regulatory agencies for approval (Thomas et al., 2015). Three monoclonal antibodies are 
now approved for MS treatment, and others are also in late stage development (breafly 
described below). And, despite a real breakthrough in treating MS, the available therapies 
are far from having sorted out the current unmet needs raised by the complexity of MS.  
Three anti-CD20 agents (rituximab, ocrelizumab, and ofatumumab) that deplete pre-B cells 
and mature B cells without affecting plasma cells or progenitor cells in the bone marrow 
have been studied in MS (Singer et al., 2016).  
- Rituximab is a human–mouse chimeric monoclonal antibody against CD20. Rituximab 
has been used off label for MS as well as neuromyelitis optica. Although rituximab 
rapidly and consistently decreases the numbers of peripheral CD20+ and CD19+ cells 
(Topping et al., 2016), a small phase II trial of intrathecal rituximab was terminated 
early because of low efficacy on the CSF biomarkers. No phase III trials of rituximab 
for MS have yet been performed. 
- Ocrelizumab and ofatumumab are both humanized anti-CD20 monoclonal antibodies. 
Ocrelizumab was the first trialed drug to meet primary and key secondary efficacy 
outcomes in a phase III PPMS study. Ocrelizumab significantly reduced the relative 
risk of 12-week CDP by 24% and 24-week CDP by 25%, decreased the volume of T2 
hyperintense lesions and reduced the whole brain volume loss compared with 
placebo. The results of all phase trials will be submitted for the approval of 
	 25	
ocrelizumab to the FDA (Coclitu et al., 2016). 
- Ofatumumab is currently used for lymphocytic leukemia, which interacts with the 
early activation of the B lymphocyte and has lower potential for antigenicity. It was 
tested in a small phase II clinical trial with promising results, showing a 99% 
reduction of MRI activity, with no serious adverse events (Sorensen et al., 2014). 
A part of the monoclonal antibodies that have been just described, other pharmacological 
agents are under clinical trials. 
Cladribine is a cytotoxic drug, an adenosine deaminase-resistant purine nucleoside, used as 
a first-line chemotherapeutic agent in the treatment of hairy cell leukemia and other 
neoplasms, in its parenteral formulation (Huynh et al., 2009). It enters cells via purine 
nucleoside transporters (Liliemark, 1997). Cladribine works preferentially on lymphocytes 
and monocytes by disrupting cellular metabolism resulting in cell death (Beutler, 1992), 
being incorporated into the DNA of the dividing cells. The recently reported results of a 
120-week extension demonstrated that in a majority of patients, the clinical benefits on 
relapses and disability as well as on MRI outcome measures of 3.5mg/kg cladribine given in 
the first two years of the trial can be maintained for at least 4 years (Coclitu et al., 2016). 
But, a recent analysis applied the 2010 McDonald criteria caused Cladribine fail to get 
regulatory approval by the EMA because of concerns over the risks of cancers in the 
CLARITY active arm (Coclitu et al., 2016). Now, PREMIERE (NCT01013350), an observational 
prospective study of patients who have participated in clinical trials with cladribine or 
other DMTs is ongoing Pakpoor et al., 2015). 
Laquinimod is an orally available carboxamide derivative, derived from linomide, a drug 
that was proved to reduce activity in RRMS, but with the cost of severe adverse events 
(Brueck and Wegner, 2011). Laquinimod was or currently is tested for neurodegenerative 
disease such as Huntington’s disease and also for relapsing remitting and progressive MS 
(Kim et al., 2015). 
Siponimod and ozanimod, two oral selective S1P receptor modulators, were recently 
successfully tested in a phase 2 trial with positive MRI outcomes (Cohen et al., 2016). 
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1.4.3 New strategies 
Although several therapies for MS are already available, a large unmet clinical need for 
more effective immunomodulatory treatments still remains in this category of diseases, but 
also for interventions able to address their neurodegenerative component, which is 
currently untreated.  
Preventing the entry of lymphocytes into the CNS and modifying the nature of the immune 
response are approaches that act on in the inflammatory component of MS, but have little 
or no effect on neurodegeneration.  
Here, new strategies and potential approaches for the treatment of MS are briefly 
described.  
 
Autologous Bone Marrow Transplantation 
Hematopoietic stem cell transplantation (HSCT) has been used in many studies on animal 
models that showed a strong immunosuppression followed by syngeneic bone marrow 
transplantation can induce long term antigen-specific tolerance (Karussis et al., 1999). 
There is evidence that high-dose immune ablation and autologous HSCT could renew the 
immune system repertoire and reinforce immune tolerance mechanisms thus having a 
clinical impact (Muraro and Douek, 2006). Although these results are promising, and 
progress has been made over the last decade in mitigating risks, there are many unknowns 
regarding the use of HSCT as a possible second-line therapy for refractory MS (Freedman 
and Atkins, 2016; Soelberg Sorensen, 2016). 
However, the benefits of this procedure would only be seen with intense conditioning 
regimens which achieve a near-complete immune ablation (Freedman and Atkins, 2016). 
Considering HSCT benefit-risk profile and the availability of highly-effective treatments 
with monoclonal antibodies, which can achieve disease control in patients with active 
disease, intense immunosuppression with HSCT should remain a third-line therapy (Soelberg 
Sorensen, 2016). It is likely that the place of HSCT in MS will be re-evaluated over the next 
years, in light of the continuously-growing spectrum of available therapies and of new 
pragmatic, prospective, controlled multicentre trials. 
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Remyelination strategies 
It is known that remyelination occurs initially in MS lesions but is inadequate, and the 
mechanism of repair in the CNS fails with time, especially in chronic disease stages 
(Franklin, 2002). The differentiation of oligodendrocyte precursor cells (OPC) into mature 
cells is essential and this process will be described in detail in Chapter 2. Remyelination 
develops in two steps: the colonization of the lesions by OPCs, and OPC differentiation into 
mature oligodendrocytes able to generate functional myelin sheath (Chari, 2007). 
Most information on these processes comes from studies on animal models (EAE and the 
cuprizone model of MS) (Zendedel et al., 2013). Remyelination can be promoted either by 
intrinsic (altering intrinsic signaling pathways, for instance through the pharmacological 
modulation of a membrane receptor) or extrinsic (acting on lesion environment) repair 
mechanisms (Rodgers et al., 2013; Keough and Yong, 2013). 
In this respect, GPR17 has been proposed as a new possible target for remyelinating 
strategies. GPR17 (that is the focus of this thesis and it will be introduced extensively in 
chapter 3) is a membrane receptor expressed by OPCs for a short-time window during their 
differentiation and it has been demonstrated to be essential for this process (Chen et al., 
2009; Fumagalli et al., 2011). An upregulation of this receptor has been reported under 
many pathological conditions with demyelinating component, thus a pharmacological 
modulation aimed at restoring the receptor levels could be a promising strategy able to 
foster remyelination (Lecca et al., 2008; Boda et al., 2011; Ceruti et al., 2011).  
Wang et al. differentiated OPCs from human induced pluripotent stem cells (iPS) and 
engrafted them in a myelin-deficient mouse model. The transplanted OPCs differentiated 
into astrocytes and oligodendrocytes, myelinated the brains of the animals, and increased 
their survival (Wang et al., 2013). However, since MS is a multifocal disease it would 
probably require repeated transplantation of the OPC in all the demyelinated regions 
(Munzel and Williams, 2013). These techniques are still under study, and their safety and 
efficacy are yet unknown. 
It is not yet clear whether remyelination completely prevents neurodegeneration but it 
does appear to restore neuronal function and at least limit neuronal degeneration (Munzel 
and Williams, 2013), therefore remyelination strategies are likely to be part of the MS 
treatments in the future.  
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Mesenchymal stem cells 
Mesenchymal stem cells (MSC) can be harvested from adult bone marrow and can be 
transplanted securely without the need for immunosuppression and with a low risk of 
aberrant proliferation. 
Mechanisms of action would include immunoregulation and anti-inflammatory changes of 
the cellular environment. It is likely that the potential therapeutic efficacy of MSC could be 
based on systemic effects as recently shown (Abramowski et al., 2016).  
A phase 1/2 open-safety clinical trial in patients with MS and with amyotrophic lateral 
sclerosis showed that intrathecal and intravenous administration of autologous MSCs is a 
clinically feasible and a relatively safe procedure which produced immediate 
immunomodulatory effects (Karussis et al., 2010). 
 
T-cell directed strategies 
It was suggested that the immune response in MS is directed at least in part against myelin 
proteins including MBP, myelin oligodendrocyte protein (MOG) and PLP (Amor et al., 1994; 
Johns et al., 1995). Although there are differences in the activation state or precursor 
frequencies of T cells from patients with MS and healthy subjects, people without MS also 
have immune responses against such antigens. However, it was suggested based on indirect 
evidence that molecular mimicry, epitope spreading and bystander activation are possible 
mechanisms to initiate and maintain disease activity. Consequently, an alternative 
treatment approach in MS could aim to selectively restore self-tolerance to auto-antigens 
via immunization (Fissolo et al., 2012) and epitope-specific induction of T cell tolerization 
(Billetta et al., 2012) or specifically by targeting regulatory T cells (Treg) signaling (Spence 
et al., 2015). A first phase I trial in humans published in 2013 showed that the antigen-
coupled cell tolerization in MS is feasible and safe (Lutterotti et al., 2013). 
 
Drug repurposing in MS 
The failure to deliver successful neuroprotective therapies in MS has led to alternative 
strategies such as drug repurposing (Vesterinen et al., 2015). By exploiting existing trial and 
regulatory data on clinical safety and efficacy, “drug rescue” (evaluating drugs at advanced 
stage of development but abandoned before approval) and “repurposing” (evaluating drugs 
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already approved for other conditions), offer the potential to reduce both the cost and 
time to achieve licensed approval status. 
Successful repurposing of drugs is not new; examples include dimethyl fumarate 
(Tecfidera)—originally marketed as a therapy for psoriasis, but later developed as a disease 
modifying therapy for relapsing-remitting MS (RRMS) (Gold R., et al, 2012). And recently, 
encouraging data suggest that phenytoin in acute optic neuritis (Raftopoulos et al., 2016) 
and amiloride in PPMS (Arun et al., 2013) could have a neuroprotective effect. 
Thus, on this basis, it is probable that repurposing drug development will play a bigger role 
in the future despite the inherent pitfalls which impact its feasibility (Giovannoni et al., 
2015). 
1.5	Animal	models	of	MS	
As mentioned earlier, the mechanism of MS is largely unknown and despite serious efforts 
are made every day, there is no cure, but only symptomatological treatments. However, 
there are several well-characterized experimental animal models that provide a profound 
insight into the pathological processes that may cause or influence MS.  
The autoimmune view of MS is strongly supported by the animal model experimental 
autoimmune encephalomyelitis (EAE), a group of disorders characterised by inflammation, 
myelin damage and neurodegeneration induced following immunisation with myein antigens 
(e.g., MOG or PLP). 
For demyelinating disorders, where the aetiological agent is due to viral infection, several 
viral models to study MS have been developed. Theiler’s murine encephalomyelitis (TMEV) 
model is based on virus-induced demyelination. Intracranial infection of susceptible mouse 
strains with TMEV results in biphasic disease of the CNS, consisting of early acute and late 
chronic demyelinating phase. The late chronic stage of demyelination in the TMEV infection 
makes this experimental model highly suitable for studying different aspects of the 
pathomechanism of MS (Denic et al., 2011). 
Remyelination, however, is better studied in toxin models, where neurotoxic agents are 
used to induce the loss of myelin sheath in certain areas in the CNS. The most frequently 
used demyelinating agents are lysolecithin, ethidium bromide and the copper chelator 
cuprizone. Despite the extensive use of these models, the clinical course, immunology and 
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neuropathology reflect only part of the pathological spectrum of MS, indicating that 
responses to therapies in animal models often cannot predict efficacy in humans. 
Below, a brief overview on the most used MS models. 
1.5.1	Experimental	autoimmune	encephalomyelitis	
Immunisation of susceptible animals with CNS antigens gives rise to a spectrum of 
inflammatory disorders collectively named EAE. Although the experimental disease in 
animals was originally termed experimental disseminated encephalomyelitis, the idea that 
the ‘disease’ was allergic gave rise to the name experimental allergic encephalomyelitis. 
More recently, allergic has been replaced by autoimmune. Despite differences in disease 
course and pathology, EAE is still the most intensely used experimental model of MS, that 
mimics MS pathology and allows a detailed insight into the immunological aspects of this 
disease. EAE has been extensively used to better understand immune-mediated mechanisms 
of demyelination and neurodegeneration in MS.  
This experimental disease can be obtained in all mammals tested so far, including 
nonhuman primates, allowing very advanced preclinical studies. Its appropriate use has led 
to the development of the most recent treatments approved for MS (See table 1.3), also 
demonstrating its predictive value when properly handled (Kipp et al., 2012).  
	
Treatment “Proof on concept” in EAE FDA approval Approved indication 
Glatiramer acetate 1971 1996 RR-MS 
Mitoxantrone 1987 2000 SP-MS worsening RR-MS 
Natalizumab 1992 
2004 
Withdrawn in 2005 
Reinstated in 2006 
RR-MS 
Table	1.3	-	Therapeutics	approved	for	preventive	treatment	of	MS	that	have	been	developed	in	the	EAE	model	
(modified	from	Denic	et	al.,	2011).	
This form of experimental encephalomyelitis displays an acute and/or chronic-relapsing, 
acquired, inflammatory demyelinating autoimmune disease. In active EAE, rodents (most 
commonly mice, rats or guinea pigs) or non-human primates are injected subcutaneously 
with a myelin related antigen/peptide (e.g. MOG, PLP, MBP) or spinal cord homogenate 
(SCH). The clinical, pathological, and immunological picture of autoimmune models of 
demyelination depends upon the mode of sensitization, the nature of the immunogen, and 
the genetic background of each species and strain (see Fig.1.3). 
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Figure	1.3	–	EAE	clinical	courses	(modified	from	Furlan	et	al.,	2009)	
Similar to MS, age, gender and environmental factors have a profound influence on disease 
susceptibility, severity and course of EAE. For example, young male SJL mice immunised 
with PLP are relatively resistant to EAE whereas older males and female SJL mice of any 
age are susceptible. Young C57BL/6 mice and Wistar rats develop acute EAE and remission 
whereas middle-age males developed severe chronic EAE (Ditamo et al., 2005; Matejuk et 
al., 2005). As in MS pregnant females show a reduced susceptibility to disease, probably as 
a result of immune suppression (Evron et al., 1984). These findings, along with the 
observation that older mice immunised in winter are more susceptible to EAE indicate an 
influence of genetics, gender and age in disease susceptibility. 
 In the classical picture of EAE, activated myelin-antigen specific CD4+T-cell clones express 
adhesion molecules, enzymes, cytokines and chemokines and their receptors inducing the 
break-down of blood-brain barrier and migrating into the CNS. Antigenic determinants 
presented by antigen presenting cells (monocytes, macrophages, dendritic cells, B cells, 
microglia, astrocytes) then recognized by myelin-antigen specific T cells, which undergo 
continuous activation and exert cytotoxic effects in the CNS. A rather simplistic picture of 
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the EAE cytokine network would suggest that TNF-a, TNF-b, IFN-g, and IL-12 (pro-
inflammatory cytokines) have a disease-promoting role, while TGF-b, IL-10, and possibly IL-
4 (anti-inflammatory cytokines) may protect from disease. A paralytic disease typically 
develops affecting predominantly the tail and hind limbs, but sometimes also the fore limbs 
(see below).  
The initial phase of disease is usually termed the acute phase, and correlates with the 
mononuclear cell infiltrates in the CNS. In species and strains where the animals recover, 
this recovery period is referred to as remission. If animals do not recover the disease is 
referred to as chronic EAE. 
A non-parametric scale with five steps is used for clinical evaluation (Fig. 1.4). Mice are 
taken from the cage by the tail and observed from the abdominal side: healthy mice extend 
their hind limbs very wide when held in this position. An asymmetric position, especially 
with one of the hind limbs retracted close to the abdomen, may represent an initial sign of 
disease. A weak tail and an unsteady gait are the signs at onset. To reveal an uncertain 
gait, it is useful to observe mice walking on a grid, like the cage cover. Healthy mice are 
quick in movements on a grid almost as on firm ground. Sick mice are unsure, move slowly, 
and often stumble. In the absence of other signs, we score the uncertain gait on the cage 
cover as 1.5. Another useful examination is that of the righting reflex. Trying to put healthy 
mice on its back results in such a quick flipping to the upright position that it is impossible 
to see the abdomen. A sick mice may have a slow, very slow, to complete impaired righting 
reflex. In the absence of other signs, we score any grade of impairment of the righting 
reflex as 2. Paraparesis (score 3) and involvement of fore limbs (score 4) are easily 
identified (Furlan et al., 2009). 
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Figure	1.4	–	EAE	clinical	evaluation	(modified	from	Furlan	et	al.,	2009)	
1.5.2	The	cuprizone-induced	experimental	demyelination	
The first experiments using cuprizone as a toxic compound were performed in the late 
1960s (Carlton, 1969). Although cuprizone was used as a chelator for copper analysis, it was 
described that cuprizone administration induced microscopic lesions in the brain 
accompanied by edema, hydrocephalus, demyelination, astrogliosis and the effects of 
cuprizone were not antidoted by administration of copper (Carlton, 1967). Based on his 
findings, most laboratories use 6–9-week-old mice and feeding with a diet containing 0.2–
0.3% cuprizone. Blakemore reported first that cuprizone causes OL degeneration 
(Blakemore, 1972) and the demyelination of the superior cerebellar peduncle (Blakemore, 
1973). Primary OL degeneration and selective regional vulnerability of the cuprizone 
regimen were described by Komoly et al (Komoly et al., 1987; Komoly et al., 1992). 
Cuprizone-induced demyelination model has attracted increasing interest during the last 
decade since contrary to other models of MS this one provides a highly reproducible system 
of primary OL apoptosis and secondary demyelination and where adaptive immune 
responses are not involved. The administration of the copper chelating agent cuprizone 
(bis-cyclohexanoneoxaldihydrazone) to mice induces spatially and temporally well-defined 
histopathological alterations in the CNS.  
Furthermore, strain-dependent susceptibility to cuprizone has been reported. For example, 
SJL mice display a unique pattern of demyelination that does not follow the profile as seen 
in C57BL/6 mice. SJL mice do not readily demyelinate at the midline within the corpus 
callosum but show greater demyelination directly lateral to midline (Taylor et al., 2009). 
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The earliest event is the appearance of megamitochondria (Ludwin, 1978), followed by only 
specific mature OL apoptosis. Cuprizone is a copper chelator, which in turn leads to 
inhibition of the copper-dependent mitochondrial enzymes cytochrome oxidase and 
monoamine oxidase. Thus, a plausible hypothesis is that disturbance in energy metabolism 
leads to apoptosis in the oligodendrocytes, which causes demyelination (Matsushima et al., 
2001). If the mice are exposed to a higher dose of cuprizone, this will lead to formation of 
megamitochondria in the liver, thus emphasizing the role of mitochondrial dysfunction in 
this model.  
The peak of the apoptotic events is between the 3rd and 10th days (Matsushima et al., 
2001) of the cuprizone challenge, but apoptotic OLs can be detected during the entire 
administration, and even during the recovery period 12 weeks post treatment (Lindner et 
al., 2009). The exact mechanism of OL apoptosis is not fully understood, and is often 
debated. However, it is generally accepted that cuprizone induces metabolic disturbances 
in OLs which leads to apoptosis involving a mitochondrial mechanism. A similar role of the 
mitochondria has been implicated in OL cell loss in MS as well (Kalman et al., 2007). 
The massive OL apoptosis is followed by extensive demyelination. The loss of myelin is 
preceded and accompanied by a down-regulation of myelin-related proteins with varying 
kinetics. For example, down-regulation of MAG expression can be seen in a few days after 
the initiation of cuprizone administration, while complete demyelination of the corpus 
callosum is usually observed after six weeks of treatment (fig. 1.5). While demyelination 
was thought to affect only particular white matter tracts (i.e. corpus callosum, superior 
cerebellar peduncle) (Komoly, 2005), other studies reveal that other regions, including the 
hippocampus, putamen, cerebellum and even distinct gray matter areas in the cortex, also 
undergo demyelination (Kipp et al. 2009). 
Another prominent pathological feature associated with OL apoptosis is the invasion of the 
demyelinated areas by activated microglial cells. These cells originate from residential 
microglia, but macrophages immigrating from the blood (Remington et al., 2007) also 
contribute to the marked numbers of phagocytic cells seen most abundantly around the 
third week of cuprizone treatment. If mice return to normal diet after five weeks of 
cuprizone exposure, demyelination is followed by a spontaneous and complete 
remyelination driven by the repopulation and maturation of OL progenitor cells (OPCs) 
(Lindner et al., 2008). If the cuprizone challenge is prolonged for 12 weeks, the degree of 
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remyelination may be limited or remyelination may even fail to occur (Lindner et al., 
2009). If it occurs, this spontaneous but incomplete remyelination begins between the 4th 
and 6th weeks of the ongoing cuprizone administration (Armstrong, 2007).  
	
Figure	1.5	–	Course	of	de-	and	re-myelination	in	the	medial	corpus	callosum	(modified	from	Gudi	et	al.,	2014)	
Histopathological features of the cuprizone-induced demyelination closely resemble those 
of the Lucchinetti et al. defined type III MS lesions (described before in paragraph 1.2.3) 
(Lucchinetti et al., 2000). The most significant similarities include a prominent OL 
apoptosis and microglial activation in the actively demyelinating lesions, the lesions are not 
perivascular and their borders are ill defined, and there is an early and profound 
downregulation of the MAG mRNA level (Morell et al., 1998). In addition, the cuprizone 
model shares common features with the earliest phases of MS lesion development as 
described by Barnett and Prineas (Barnett et al., 2004) and Henderson et al (Henderson et 
al., 2009), where first, apoptosis of OLs occurs in regions with intact myelin. As the 
pathology further evolves, early demyelinating lesions are invaded by scavenging 
macrophages (innate immune response), which phagocytose and clean up degraded myelin.  
Considering the above histopathological features, the cuprizone model is highly suitable for 
studying basic mechanisms of acute and chronic demyelination and remyelination, exploring 
the pathophysiology of OL apoptosis, and testing preclinically new interventions for 
promoting remyelination and repair in MS lesions. 
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Chapter	2		
Oligodendrocytes	
	
2.1	Oligodendrocytes:	the	myelin-forming	cells	in	the	CNS		
The CNS contains two major types of specialized cells, neurons and glial cells (Figure 2.1). 
Neurons are regarded as the elements mediating the electrical activity in the form of 
action potentials and are responsible for the relay of information throughout the nervous 
system. Neuroscience research of the past has mainly focused on this cell type, since until 
recently glial cells were believed to provide only structural support to neurons. However, it 
is now becoming increasingly clear that glial cells have active functions in the nervous 
system, as demonstrated by numerous experimental evidences showing that glial cells play 
a role in synaptic development and activity, provide guidance of neuronal migration and 
process outgrowth and influence the electrical activity of neurons. Thus, it is now 
recognized that different types of glial cells fulfil distinct tasks and are essential for the 
proper functioning of neural circuits.  
Based on morphology, function and location in the nervous system, glial cells are classified 
in three main categories: astrocytes, microglia and oligodendrocytes (OLs) (Barres, 2008; 
Allen and Barres, 2009).  
Astrocytes are star-shaped cells which extend many processes that contact both blood 
vessels and neurons; they provide leading structures during development and represent 
important elements for controlling the composition of the extracellular space mediating 
signals between the brain endothelium and the neuronal membrane.  
Microglial cells are the resident immuno-competent cells of the nervous system. They have 
crucial functions in surveillance and homeostasis of CNS, reacting to damage and infection, 
by removing cellular debris and actively participating to neural tissue remodelling after 
injury.  
OLs are the myelin-forming cells of the CNS that ensure the saltatory conduction of the 
nerve impulses in the WM. They are post-mitotic glial cells with small number of 
cytoplasmic processes, whose name comes from the Greek roots oligo, meaning ‘few’, 
dendro meaning ‘branch’, and kytos which denotes ‘cell’. This term was first introduced by 
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Rio Hortega to describe those neuroglial cells that show few processes in material stained 
by metallic impregnation techniques.  
OLs are also involved in neuronal development and survival, in the regulation of 
extracellular ion concentrations, in the distribution of potassium channel along the axons 
and in the axonal transport. Moreover, some OLs form synapses with neurons and are 
actively involved in CNS functions (Barres, 2008; Emery, 2010).	
 
Figure	2.1	–	Glial	populations	within	CNS	
In 1992, Rio Hortega classified OLs in four categories based on the characteristics of the 
number and orientation of their cellular processes, the shape and size of their somata, the 
size of the axons they were associated with, and their distributions within the CNS (Rio-
Hortega, 1928). Type I and II OLs are indistinguishable and have four or more primary 
processes that branch repeatedly to myelinate 10-30 axons less than 2 µm in diameter. 
Type I OLs can be found in the forebrain, cerebellum and spinal cord, whereas type II OLs 
are observed only in WM. Type III OLs have large cell bodies, often applied directly to an 
axon, with one or more thick primary processes that rarely branch and myelinate a small 
number of axons, usually less than five, with external sheath diameters ranging 4 to 15 µm. 
They are localized in the cerebellar peduncles, the medulla oblongata and the spinal cord. 
Type IV OLs are similar to type III OLs but not have processes and form a single long myelin 
sheath over a large-diameter fiber; they are restricted to tracts containing the largest 
diameter fibers and occur near the entrance of nerve roots into the CNS (Baumann and 
Pham-Dinh, 2001).  
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This first section will be focused on this latter glial cell type. Specifically, the embryonic 
and postnatal development of OLs and their functional roles in physiological and 
pathological conditions will be described and discussed. 
2.1.1	Embryonic	and	postnatal	development	of	OLs	
OLs are ubiquitous in both the WM and grey matter (GM) of brain and spinal cord and most 
of our knowledge about the biology of OLs and myelin derives from studies in rodents. 
These cells originate from pluripotent neuroepithelial cells of neural tube, that give rise to 
committed oligodendrocyte precursor cells (OPCs). These cells are able to divide and 
migrate throughout the CNS. In mouse, OPCs first appear in the embryo starting at about 
embryonic day (E) 12.5 in the ventral ventricular zones of the spinal cord, where they 
originate together with motoneurons from a common class of precursor cells (pMN, 
precursors motoneuron), defined by the expression of the transcription factor Olig2 (Lu et 
al., 2002; Takebayashi et al., 2002; Zhou et al., 2000). This OPC production is dependent 
on Sonic hedgehog (Shh) signaling and bone morphogenetic proteins. At about E15, 
generation of a secondary wave of precursors starts in more dorsal regions of spinal cord by 
trans-differentiation of radial glia (Lu et al., 2002) and this generation is independent on 
Shh pathway (Cai et al., 2005). 
The origin of OPCs in the brain is instead more complex. In the embryonic telencephalon 
three different waves of OPC generations were observed, temporally progressing from 
ventral to dorsal regions (Kessaris et al., 2006). The first wave starts at E12.5 (overlapping 
with the appearance of OPCs in the spinal cord) in the medial ganglionic eminence (MGE) 
and in the anterior entopeduncular area (AEP). The second wave follows the first at E15.5, 
taking place in the lateral and caudal ganglionic eminence (LGE and the CGE) and final one 
arises at postnatal day 0 (P0) directly from the cortex (Kessaris et al., 2006). 
These three distinct waves of OPCs originate from three distinct types of neural 
progenitors, expressing different transcription factors. OPCs from the first wave express 
platelet-derived growth factor receptor alpha (PDGFRα) reflecting their dependence on 
PDGF-AA for survival and proliferation (probably the most important molecule controlling 
the number of OLs in vivo); these cells successively migrate to the cortex (at E16) and, 
finally, disappear completely at P10. OPCs from second wave start at E15.5 and are 
generated from Gsh2-expressing progenitors and OPCs from third wave start around birth 
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(P0) and derived from Emx1-expressing progenitors (Figure 2.2). This fine embryonic 
regulation of OPC origin led once again to the idea of distinct subsets of OPCs, devoted to 
different functions. However, so far no study has correlated a distinct origin to a specificity 
in OPC behavior in the postnatal and adult CNS. Future research will clarify this aspect. 
After the formation, OPCs migrate extensively from oligodendrogliogenic niches and 
colonise the entire CNS. The migration of these precursors is likely to be mediated by 
specific directional and substrate cues. Ventrally-generated OPCs predominate in the spinal 
cord, while the dorsally-generated ones prevail in the telencephalic vesicles; this 
distribution may reflect a compensatory redundancy to ensure rapid and efficient 
myelination throughout the entire CNS (Richardson, 2006). It is known that OPCs migrate 
along pre-existing axons. However, when these pre-existing axons are transected, the cell 
biology of OPCs does not change and they migrate properly, and even extensively, 
demonstrating that OPCs could respond to signals other than those expressed by viable 
axons (de Castro et al., 2005; Sugimoto et al., 2001; Ueda et al., 1999). 
Figure	 2.2	 -	 	 Origins	 and	 migration	 of	 oligodendrocyte	
precursors	 in	 the	 rodent	 cervical	 spinal	 cord	 and	
telencephalon. (a)	 In	 the	 mouse	 spinal	 cord,	 OPCs	 are	
generated	 from	 pMN	 in	 the	 ventral	 ventricular	 zones	 (1),	
starting	 at	 about	 embryonic	 day	 (E)12.5.	 At	 about	 E15,	
generation	of	a	secondary	wave	of	precursors	starts	 in	more	
dorsal	regions	by	trans-differentiation	of	radial	glia	(2).	(b)	In	
the	 telencephalon,	 the	ventral-most	precursors	 in	 the	medial	
ganglionic	 eminence	 are	 produced	 from	 about	 E12.5	 (1),	
production	 of	 the	 lateral	 ganglionic	 eminence	 derived	
precursors	 starts	a	 few	days	 later	 (2),	 and	production	of	 the	
cortex-derived	 precursors	 occurs	 mainly	 after	 birth	 (3)	
(Richardson	et	al.,	2006).		
To date, three different classes of secreted molecules seem to be involved in the migration 
of OPCs: growth factors - like PDGF-AA, FGF2 (Simpson and Armstrong, 1999; Bribian et al., 
2006); chemotropic molecules - like netrins and secreted semaphorins (Spassky et al., 
2002); and the chemokine CXCL1 (Miller et al., 2002; De Castro et al., 2013). Although 
there is no doubt that these factors play a role in OPC migration, the exact mode of action 
of these factors is still a matter of controversy, in part due to differences in experimental 
models, culture systems, and time points studied. OPC migration is not only controlled by 
secreted molecules, but is also regulated by contact-mediated mechanisms involving many 
different extracellular matrix proteins and cell surface molecules, N-cadherins, and 
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possibly even additional, yet unidentified molecules. From all these different molecules, a 
common theme evolves, demonstrating contact-based migration of OPCs over extracellular 
matrices, axonal tracts, and astrocytic surfaces. Once located at their final destination, 
some OPCs persist into adulthood, while the vast majority differentiates to myelin-
producing oligodendrocytes (Bradl and Lassmann, 2010). 
Globally, the factors described above, highlight how complex and fine-tuning is OPC 
migration. The control of all these mechanisms ensures the proper migration of these 
precursors and allow them to migrate long distances and to populate the whole brain and 
spinal cord.  
In humans, myelination is a largely postnatal process and it continues well into adulthood. 
Practicing a skill can increase the volume of WM regions employed in carrying out the task 
and, conversely, social isolation, with reduced external stimuli, leads to hypomyelination 
and impaired cognitive functions (Blumenfeld-Katzir et al., 2011; Gibson et al., 2014; Liu et 
al., 2012; Makinodan et al., 2012; Sampaio-Baptista et al., 2013). Thus, external stimuli 
may modulate myelination, which in turn could affect axonal transmission velocity and 
neural processing (Bergmann and Frise´ n, 2013; Fields, 2008, 2012). In a recent work, 
Yeung and colleagues demonstrates that the number of OLs in the corpus callosum is 
established in childhood and remains stable after that.  
They found that the number of OPCs is highest in the youngest individuals and dropped 
during early childhood. Shortly after birth, there are very few mature OLs, but the number 
increased rapidly in the perinatal period and approach stable numbers at about 5 years of 
age (88% of the final number). The final number of OLs is reached at 9 years of age. After 
this age the number of OLs stays largely stable throughout the rest of the human lifespan. 
The OL population in human WM is remarkably static once the full complement is 
established, with only 1/300 OLs being exchanged annually, and OL generation cannot 
account for the increase in myelin volume in response to experience in humans. They 
conclude that myelin remodeling in WM is independent of cell turnover and mainly carried 
out by mature OLs in humans (Yeung et al., 2014). 
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2.1.2	Oligodendrogliogenesis		
During migration, the precursors maintain the capability to proliferate but, then, when they 
reach their final destination, exit the cell cycle and start differentiating in order to acquire 
a mature phenotype for the formation of myelin sheaths (Greenwood and Butt, 2003). 
OPC differentiation is a very complex process during which cells encounter their fate 
through a series of fine regulated maturation stages, characterized by changes in cell 
morphologies, cell cycle exit and by the expression of genes and proteins required for 
maturation and myelination (Fig. 2.3). At the beginning, OPCs have a bipolar morphology 
and express PDGFR-α, the proteoglycan NG2 (glial antigen 2), the isoform DM-20 of the 
proteolipidi protein (PLP) and the gangliosides A2B5 and GD3 (Baumann and Pham-Dinh, 
2001). Other important markers of these cells are Olig1/Olig2, that are transcriptional 
factors present throughout all the development and the maturation process. Although these 
two transcriptional factors are structurally related, their biological functions are only 
partially redundant. Olig1 has a minor role in OPC specification and development, but it 
plays a pivotal role in terminal differentiation. By contrast, Olig2 functions at earlier 
developmental stages. Initially, Olig2 acts to oppose cell differentiation and sustains the 
replication competent state so as to expand the pool of progenitors. At later stages of 
development, Olig2 promotes the fate choice decision to form early oligodedrocyte 
progenitors (Meijer et al., 2012). However, it has been demonstrated that OPC terminal 
differentiation in the pMN domain requires the presence of both Olig1 and Olig2 and in 
some regions of CNS the role of ones prevail on the other (Wegner et al., 2008). Zhou and 
co-workers demonstrated that, during the last phase of OPC development, there is a 
reduction of Olig2 expression in parallel with an increase of Olig1, while Lu and its team 
claim that the expression of both genes remains throughout all the development in the 
adult CNS too (Wegner et al., 2001). 
In the developmental brain, cells of the premyelinating stage assume a more complex 
morphology with many branching processes and are characterized by the expression of the 
sulfatide O4 (oligodendrocyte marker O4), GPR17, the tetraspanin protein CD9 and DM20. 
They start appearing in the corpus callosum and, then, they distribute in all the cortical 
parenchyma between P4 and P10; particularly at P7 all NG2-positive cells express O4 
(Levine et al., 1993; Dawson et al., 2003). Subsequently, pre-oligodendrocytes become 
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immature OLs. In this stage, cells start expressing the galactosylceramide GalC, the myelin-
associated enzyme 2’, 3’-cyclic nucleotide 3’-phospho-diesterase (CNPase) and the 
ribosome inactivating protein (RIP), while they start losing the expression of NG2, A2B5, 
GD3 and GPR17. Pre-oligodendrocytes further progress to the mature stage during which 
they synthetize the myelin basic protein (MBP), the myelin associated glycoprotein (MAG) 
and the mature isoform of PLP1 (PLP). Maturing OLs transiently express the CC1 (APC 
immunogen, clone CC1 or “CC1”) during normal oligodendroglial development and 
oligodendroglial regeneration (Lang et al., 2013).  These cells are not able to form myelin 
yet, since the formation of myelin sheaths requires the contact with neuronal axons. After 
the establishment of this contact, cells become myelinating cells and start expressing the 
myelin oligodendrocyte glycoprotein (MOG) (Solly et al., 1996) and the pi-isoform of 
glutathione-S-transferase (GSTp) (Tansey et al., 1991). 
	
Figure	2.3	–	OPC	differentiation	process.	Schematic	representation	of	the	developmental	stages	of	the	OL	lineage	
(adapted	from	Traiffort	et	al.,	2016).	
2.1.3	Regulation	of	OL	differentiation	and	myelination	
As described before, myelin may exhibit substantial plasticity throughout adult life. This 
has sparked renewed interest in the myelination process given that this plasticity may have 
profound implications for neural functioning. Every aspect of an OL’s life is largely 
influenced by neuronal and astroglial signals which, in turn, regulate OL survival, 
proliferation, myelination rate and programmed cell death. An increasing number of studies 
highlighted the importance of one factor rather than others, in the control of OL behaviour. 
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It is extremely difficult to extrapolate to in vivo conditions, as multiple factors may act in 
concert to achieve the fine regulation of the complex process of OL development and 
myelination. Combinations of factors often produce effects that are significantly different 
from those seen with any one factor alone (Baumann and Pham-Dinh, 2001; Emery, 2010). 
Here it will be summarized extrinsic and intrinsic signalling mechanisms controlling OL 
differentiation and myelination (Fig. 2.4).   
Extrinsic signaling mechanisms  
- Extracellular ligands and secreted molecules. The simplest mechanism for 
determining whether an individual axon is myelinated would be the expression of 
inhibitory or permissive cues for myelination on the surface of the axon itself, with 
important benefit of allowing control of myelin at the subcellular level, explaining 
how individual axons proximal to an oligodendrocyte can be myelinated or not. For 
instance, Jagged, which signals via Notch in OPCs (Wang et al., 1998), PSA-NCAM 
(Charles et al., 2000), and LINGO-1 (Mi et al., 2005), are all axonal ligands that 
inhibit either OPC differentiation or myelination. On the contrary, the axonal 
expression of neuregulins is largely dispensable for myelination (Brinkmann et al., 
2008).  
In addition to the above factors, it is almost certain that a number of extracellular 
ligands that modulate CNS myelination remain to be identified. For instance, GPR17 
is transiently expressed during oligodendrocyte differentiation and orchestrates the 
transition between immature and myelinating oligodendrocytes (Chen et al., 2009). 
Indeed, GPR17 inhibition, by either antagonists or siRNAs, impaired the normal 
program of OPC differentiation (Fumagalli et al., 2011).  
The chemokine CXCL12 (also known as SDF-1) and its receptor CXCR4 have well 
known roles in the patterning and function of the immune and nervous systems 
where they localize various cell types to specific microenvironments (Klein et al., 
2004). In the last years, several in vitro and in vivo studies demonstrated roles for 
CXCL12/CXCR4 in the migration and maturation of OPCs (Patel et al., 2010; 
Dziembowska et al., 2005). 
- Neuronal activity. In addition to genetically programmed extracellular ligands, there 
is evidence that myelination is at least in part driven by the level of electrical 
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activity in the axons themselves. Neuronal activity may modulate the surface 
expression of the above mentioned axonal ligands or cytokines. Alternatively, release 
of adenosine by active axons may activate purinergic receptors on OPCs and promote 
their differentiation and myelination (Stevens et al., 2002). Because OPCs express 
ionotrophic glutamate receptors and voltage-gated ion channels (Barres et al., 1990), 
they can respond to this stimulation with a depolarization event not unlike the 
action potential of a neuron. This suggests an elegant mechanism in which activity of 
unmyelinated axons is associated with direct synaptic release from axo-glial synaptic 
junctions onto adjacent OPCs, which differentiate and myelinate the axon at a 
certain signal threshold. 
Intrinsic signaling mechanisms 
- Transcriptional regulation. The initial specification of the oligodendrocyte lineage is 
reliant on the transcription factor Olig2; ventrally derived OLs (and lower motor 
neurons) are derived from Olig2-expressing subventricular zone progenitors, and the 
oligodendrocyte lineage is absent in Olig2-null mice (Zhou et al., 2001; Lu et al., 
2002). Subsequently, the downstream induction of a number of transcription factors, 
most notably Olig1, Ascl1, Nkx2.2, Sox10, YY1, and Tcf4, is required for the 
generation of mature, postmitotic oligodendrocytes (Wegner, 2008). All these factors 
are present in OPCs as well as in postmitotic OLs, with the exception of Tcf4, which 
is transiently expressed during differentiation (Fancy et al., 2009; Ye et al., 2009). 
- Chromatin remodeling. OL differentiation is also regulated at the level of chromatin 
remodeling by histone deacetylases (HDACs), as pharmacological inhibition of HDAC 
activity in postnatal rats causes a delay in OL differentiation and myelination (36). 
Histone deacetylases likely promote oligodendrocyte differentiation by inhibiting the 
expression of pathways and genes that otherwise act to block differentiation. 
- miRNAs. Post-transcriptional control of gene expression by microRNAs also plays a 
pivotal role in controlling CNS myelination. Use of microRNA profiling identified 
several microRNAs, most notably miR-219 and miR-338, that are induced concurrent 
with OL differentiation. These microRNAs target genes that usually act to maintain 
OPCs in the undifferentiated state, including PDGFRa, Sox6, and Hes5 (Dugas et al., 
2010; Zhao et al., 2010). Recently, miR-125a-3p, a developmentally regulated 
miRNA, has been proposed as a new actor of oligodendroglial maturation. In cultured 
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OPCs, over-expression of miR-125a-3p by mimic treatment impairs while its 
inhibition with an antago-miR stimulates oligodendroglial maturation (Lecca et al., 
2016). 
	
Figure	2.4	–	Schematic	representation	of	 the	oligodendrocyte	 lineage	showing	some	of	 the	 intrinsic	and	extrinsic	 factors	
that	influence	oligodendrocyte	differentiation	and	the	myelination	of	individual	axons	(adapted	from	Emery,	2010).	
2.1.4	Purinergic	signaling	and	oligodendrogliogenesis	
Many studies have revealed a role for purinergic signaling in OL development and death 
(Butt, 2006; Agresti et al., 2005; Fumagalli et al., 2011; Fumagalli et al., 2016). Since the 
early ‘90s, ATP has been identified as an important activity-dependent axonal signal that is 
able to activate purinergic receptors, increasing Ca2+ concentrations in OPCs and 
differentiated OLs. These cells express several P2X (P2X1, P2X2, P2X3, P2X4, P2X7) and P2Y 
(P2Y1, P2Y2, P2Y6, P2Y12, P2Y13) receptors. Among these, P2X7 and the ADP-sensitive 
P2Y1 have been identified as the main ionotropic and metabotropic P2 receptor active in 
OPCs (Agresti et al., 2005). In addition, OPCs have all four adenosine receptors (Fields and 
Burnstock, 2006). 
Adenosine has been demonstrated to act as a potent neuron-glia transmitter, able to inhibit 
OPC proliferation, stimulate differentiation and promote the formation of myelin in both 
dissociated culture and cerebellar organotypic slice (Stevens et al., 2002). Indeed, upon 
application of adenosine, the incorporation of BrdU or 3H-thymidine in NG2+-OPC nuclei 
decreases significantly, even in presence of potent mitogenic factors such as PDGF and 
bFGF. In parallel, OPCs start to show a more complex morphology and the expression of O4 
and O1 (Stevens et al., 2002). Similarly, Agresti and colleagues (2005) demonstrated that 
ATP and ADP are able to inhibit OPC proliferation in vitro, both in purified cultures and in 
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cerebellar tissue slices. ATP and ADP, but not UTP have been shown also to induce OPC 
migration in vitro in dose-dependent manner. The effects of ATP and ADP on cell migration 
and proliferation are mediated by the ADP-sensitive P2Y1 receptor, as the P2Y1 antagonist 
MRS2179 completely prevents these changes (Agresti et al., 2005). Moreover, purinergic 
signaling has been found to stimulate myelination at later stages of OL development, 
through an indirect mechanism involving astrocyte release of promyelination factors 
(Ishibashi et al., 2006). In this respect, it has been demonstrated that upon treatment with 
ATP, 2-methylthio ATP and α,β-methylene ATP, astrocytes are induced to produce the 
leukemia inhibitory factor (LIF) (Yamakuni et al., 2002; Ishibashi et al., 2006), a cytokine 
belonging to the CNTF family, which has been shown to stimulate myelination in 
OPC/dorsal root ganglia (DRG) co- cultures (Ishibashi et al., 2006; Stankoff et al., 2002). 
Collectively, these findings revealed an important and positive role for purinergic signaling 
in OL development. 
However, ATP signaling through P2X7 receptors has been demonstrated to mediate OL 
apoptosis (Matute et al., 2007; Neary and Zimmermann, 2009; Domercq et al., 2010). It has 
been shown that differentiated OLs of spinal cord and optic nerve have a robust expression 
of P2X7 (Matute et al., 2008). P2X7 channel opening causes rapid depolarization, Ca2+ influx 
and loss of Na+ and K+ gradients. Thus, its activation can amplify glutamate-receptor 
mediated excitoxicity. Matute and colleagues have demonstrated that ATP signaling can 
trigger OL excitoxicity through the activation of P2X7 receptors (Matute et al., 2007). 
Moreover, it has also been showed that the OL death induced by the activation of P2X7 
receptor may have a role in the pathogenesis of diseases characterized by demyelination, 
such MS. Accordingly, sustained activation of P2X7 receptor in vivo has been shown to cause 
white matter lesions that are reminiscent of the major features of MS plaques, as 
characterized by OL death, intense microgliosis, demyelination and axonal damage. These 
features indicate that excess of extracellular ATP as a consequence of progressive tissue 
damage in MS may in turn aggravate the development of the pathology. Indeed, 
administration of Brilliant blue G, a P2X7 antagonist, in EAE mouse model inhibits 
demyelination and restores axonal conductance (Matute et al., 2007; 2008). This finding 
can be highly relevant for understanding the etiology of MS, since an increased P2X7 
expression has been detected also in normal appearing axonal tracts in post-mortem tissues 
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from MS patients, suggesting that the elevated expression of this purinergic receptor may 
be a risk factor associated with early lesion formation in this disease (Matute et al., 2007). 
Also the four adenosine receptors take part to OPC differentiation are involved in some OL 
diseases. For example, the deletion of A1 receptor induces a severe demyelination and 
causes a progressive form of EAE (Tsutsui et al., 2004). Similarly, the continuous activation 
of A1 receptor in the brain reduces the MBP expression and induces a damage in the white 
matter (Turner et al., 2003). 
Besides the role of purines in OL development and differentiation, a number of very recent 
studies have demonstrated the existence of a pyrimidinergic signaling mediated by uracil 
nucleotides (i.e. UDP and UTP) and their sugar conjugates (i.e. UDP-glucose and UDP- 
galactose) which has been also reported to modulate OPC proliferation and differentiation 
(Lecca and Ceruti, 2008). In this respect, UDP, UDP-glucose and UDP-galactose have been 
shown to act as endogenous agonists at the P2Y-like receptor GPR17 (Ciana et al., 2006; 
Benned-Jensen and Rosenkilde, 2010), an important regulator of OL maturation (Lecca et 
al., 2008; Ceruti et al., 2011; Fumagalli et al., 2011). The role of this receptor in OL 
development will be described in detail in the paragraph 3.4.1. In conclusion, the current 
data suggest that ATP and other nucleotides, that are released in high concentrations 
during inflammatory events and after cell death, may take part to the reparative processes 
in the diseases characterized by demyelination (Lecca et al., 2012). 
	
2.1.5	Structure	and	formation	of	myelin	sheath	
The myelin sheath around most axons constitutes the most abundant membrane structure in 
the vertebrate nervous system. Its unique composition (richness in lipids and low water 
content allowing the electrical insulation of axons) and its unique segmental structure 
responsible for the saltatory conduction of nerve impulses and insulation of nerve fibers in 
the vertebrate system. High-speed conduction, fidelity of transfer signaling on long 
distances, and space economy are the three major advantages conferred to the vertebrate 
nervous system by the myelin sheath, in contrast to the invertebrate nervous system where 
rapid conduction is accompanied by increased axonal calibers. The importance of myelin in 
human development is highlighted by its involvement in an array of different neurological 
diseases such as leukodystrophies and MS in the CNS and peripheral neuropathies in the 
peripheral nervous system (PNS). Moreover, in recent years, myelin has also generated new 
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interest for its involvement in normal cognitive function, learning and intelligence quotient 
and as an unexpected contributor to a wide range of psychiatric disorders, including 
depression and schizophrenia (Fields, 2008). 
Myelin is a spiral structure composed of extensions of the OL plasma membrane. 
Myelinating OLs send out sail-like extensions of their cytoplasmic membrane, each of which 
forms a segment of sheathing around an axon, the myelin sheath. This myelin sheath is 
made up of two different layers: the major dense line (dark layer) formed by the 
cytoplasmic surfaces of the expanding myelinating processes of the OL and the double 
intraperiodic line constituted by the overlapping of the outer leaflets of OL membranes 
(Baumann and Pham- Dihn, 2001). 
Myelin has a chemical composition very close to that of cellular plasmatic membranes but it 
has a peculiar lipid-to-protein ratio: it consists of 70% lipids and 30% proteins. The specific 
constituents of myelin, glycolipids and proteins are formed in the OL. 
Concerning lipids, myelin contains cholesterol, phospholipids, and glycolipids in molar 
ratios ranging from 4:3:2 to 4:4:2. On the cytoplasmatic side of the membrane there are 
phospholipids and on the extracellular side there are glycolipids, cholesterol and among 
them long chain fatty acids. One of the major characteristics of the myelin lipids is their 
richness in glycosphingolipids, in particular galactocerebrosides (i.e. galactosylceramides, 
GalC) and their sulfated derivatives, sulfatides (i.e. sulfogalactosylceramides). 
The major CNS myelin proteins MBP and PLP (and the immature isoform DM-20) are low-
molecular-weight proteins and constitute 80% of the total proteins (fig. 2.5). MBP 
constitutes as much as 30% of the total proteins and is present in various isoforms of 
different molecular masses. The main role of MBP is to compact membrane during myelin 
maturation, whereas PLP and DM20 are mainly myelin constituents. 	
Another group of myelin proteins, insoluble after solubilization of purified myelin in 
chloroform-methanol 2:1, have been designated as the Wolfgram proteins, since their 
existence was suspected already in 1966 by Wolfgram (Wolfgram, 1966). One of these 
proteins is the CNPase. This is an enzyme representing the 4% of total myelin proteins and 
known to hydrolyzes artificial substrates 2’,3’-cyclic nucleotides into their 2’-derivatives. 
Finally, several glycoproteins are present in myelin, such as MAG and MOG. MAG is 
quantitatively a minor constituent, representing 1% of the total protein found in myelin 
isolated from the CNS and 0.1% in the PNS. In the adult rat CNS, MAG is confined to the 
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periaxonal collar of the myelin sheath, whereas a larger distribution across different 
regions of PNS myelin has been reported.  
 
 
Figure	2.5	–	Schematic	representation	of	myelin	structure	(modified	from	Laule	et	al.,	2007)	
 
MOG was first identified by a polyclonal antibody directed against an antigen called M2 that 
induces EAE in the guinea pig. It was later identified as a minor glycoprotein specific for 
CNS myelin and further characterized by immunological methods, immunohistochemistry, 
and Western blot (WB), using a mouse monoclonal antibody against glycoproteins of rat 
cerebellum. MOG is only present in mammalian species and is highly conserved between 
species (Baumann and Pham-Dinh, 2001).  
Myelination consists of the formation of a membrane with a fixed composition and specific 
lipid-protein interactions, allowing membrane compaction and the formation of the dense 
and intraperiodic lines of myelin. Therefore, myelination also needs activation of numerous 
enzymes of lipid metabolism necessary for the synthesis of myelin lipids, of synthesis and 
transport of specific protein components of myelin or their mRNAs to the OL processes. 
Individual OLs myelinate up to sixty axons by extending their cytoplasmic membrane and 
forming a compact wrapping in segments called internodes (Peters, 1964; Remahl and 
Hildebrand, 1990). Between two internodes there is a gap called the node of Ranvier. At 
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these nodes, voltage-gated sodium channels are clustered to conduct action potentials, 
resulting in a conduction phenomenon called saltatory conduction. Myelination permits 
nerves to conduct action potentials faster and for longer distances, since the insulation 
provided by the myelin sheaths reduces the current flow across the axonal membrane and 
increases its transverse resistance. In addition, the saltatory conduction of action potentials 
from node to node reduces the metabolic requirements of the neurons and increases 
conduction velocity (Poliak and Peles, 2003). 
The development of OLs and myelination of individual axon is a highly regulated process 
controlled by a number of mechanisms that have been described in paragraph 2.1.3. 
The following sequential steps characterize the myelination process: 1) the migration of 
OPCs to axons that are to be myelinated and their differentiation into highly ramified cells; 
2) the adhesion of the OL processes to the axon, the spiraling of the process around the 
axon, with a predetermined number of myelin sheaths and the recognition of the space not 
to be myelinated, i.e., the nodes of Ranvier; 3) the compaction of the myelin layers 
resulting in the formation of the mature myelin sheath. 
During the first step, the preoligodendroglial multiprocessed cells settle along the fiber 
tracts of the future white matter, maintaining the ability to divide. Then, these 
preoligodendrocytes become immature OLs, characterized by the acquisition of specific 
markers (see paragraph 2.1.2) and, then, ready for myelination. The exact mechanism 
through which axons are wrapped and myelinated by OLs has not been fully elucidated. 
Several theories have been put forward over the past few years to explain how myelination 
takes play. Two models have been proposed (Fig. 2.6). In the first, the leading edge of the 
OL spreads along the axon in a sheet like manner, concludes an initial wrap, and then 
moves underneath the growing sheet. In the second, the process remains compact and, only 
when a sufficient number of wraps have been generated by turns around the axon, extends 
laterally into overlapping sheets. These two theories are clearly not mutually exclusive, and 
intermediate mechanisms might exist. 
The subsequent compaction phase is perhaps the most important part of the myelin sheath 
formation, because it involves the extrusion of the cytoplasm and both intracellular and 
extracellular sheet interconnection by specialized proteins, and is thus responsible for the 
highly specific insulating function of the sheath. 
	 51	
Both models indicate that the formation of myelin requires important morphological 
changes of OLs which are mediated by alteration of the cytoskeleton (Bauer et a., 2009). In 
fact, during the first stage of myelination, the extension and the branching of OL processes 
need the reorganization of the cytoskeleton mediated by extracellular signals, such as bFGF 
and PDGF secreted by neurons and astrocytes and extracellular matrix molecules such as 
fibronectin, vitronectin, collagen and laminin. Besides the pronounced cytoskeletal 
remodeling, the process outgrowth requires the extension of the membrane surface and 
some alterations in membrane composition. Among these, one prominent feature is the 
emergence of specialized microdomains in the sheets, termed lipid rafts. Oligodendroglial 
lipid rafts consist of a tightly packed array cholesterol and glycosphingolipids and 
phospholipids with saturated acyl chains. The role of lipid rafts is not so clear. Two lines of 
evidence suggest that one role of rafts must be to direct cytoskeletal assembly for 
myelination after axo-glial contact; the second ones is to recruit myelin protein. Finally, 
important morphological changes are also observed in the last stage of myelination, the 
compaction of the myelin sheath. This step requires retraction, disassembly or 
reorganization of the cytoskeleton and, concomitantly, relocation of bulky cellular 
organelles located in the peripheral processes (Bauer et al., 2009). 
	
	
Figure	 2.6	 –	 Scheme	 representing	 the	 two	models	 of	myelination.	
After	 contact	 formation	 of	 an	 OL	 process	 with	 an	 axon	 (A),	 the	
process	could	 flatten	 into	a	broad	sheet,	wrap	around	the	axon	(B),	
and	 then	move	 underneath	 itself	 (C)	 to	 form	 the	multiple	 layers	 of	
the	mature	myelin	sheath	(G).	Alternatively,	 the	process	could	wrap	
around	 the	 axon-like	 twine	 around	 a	 post	 (D),	 and	 once	 the	
appropriate	 number	 of	 wraps	 has	 formed,	 flatten	 out	 and	 move	
laterally	 (E,	 F)	 to	 conclude	 sheath	 formation.	 From	 the	 images,	 it	
does	become	apparent	that	these	models	are	not	mutually	exclusive,	
but	 that	 intermediate	 events	 might	 contribute	 to	 myelination.	 (H)	
depicts	 a	 longitudinal	 section	 through	 a	myelinated	 axon,	 detailing	
the	 different	 layers	 of	 the	 compact	myelin	 sheath,	with	 cytoplasm-
containing	paranodal	loops	at	either	end	(from	Bauer	et	al.,	2009).		
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2.3	Demyelination	and	re-myelination	
	
2.3.1	Demyelination	and	re-myelination	mechanisms	
As previously described, myelin integrity plays a fundamental role in the transmission of 
electrical impulses and it is the result of the proper ensheathment of axons by myelinating 
cells. OL degeneration causes a pathological process called demyelination. At present, too 
little is known about the etiology of many demyelinating disorders to enable a precise 
pathological classification. The alteration and the loss of axonal ensheathment may have 
different origin and may be caused by genetic defects, infectious agents, autoimmune 
reactions, chemical agents exposure or unknown factors. 
Demyelination can be regarded as either primary or secondary. The primary form destroys 
or damages myelin or the myelin-forming cells, whereas the axons are relatively normal, at 
least in the early stages. On the other hand, secondary demyelination (also known as 
Wallerian degeneration) involves damages to neurons or axons, followed by breakdown of 
myelin. 
From a clinical perspective, there are two major causes of primary demyelination in the 
CNS: genetic abnormalities that affect glia (e.g. leukodystrophies), and inflammatory 
damage to myelin and OLs (e.g. MS). Concerning the genetic diseases, they usually appear 
in childhood with generalized neurological symptoms, such as changes in gait, muscle tone 
and cognition, and can be subdivided into those that result from defects of lysosomal 
function (for example, metachromatic leukodystrophy and Krabbe’s disease) or perioxsomal 
function (adrenoleukodystrophy), those that result from abnormal OL myelinogenesis, that 
is due to deficiencies in or misfolding of key myelin proteins (hypomyelinating 
leukodystrophies, such as Pelizaeus–Merzbacher disease) and those that result from defects 
in the astrocytes that provide trophic support for myelinating OLs (Alexander’s disease and, 
probably, vanishing white matter disease). 
As previously described, during the initial phase of pathological demyelination, neurons 
remain intact and they can respond to the loss of myelin with the redistribution and the 
insertion Na+ channels along the denuded axolemma, to allow non saltatory conduction 
along the demyelinated segment. This compensatory mechanism allows the transmission of 
electrical impulse, even though it is less efficient than normal transmission, but impairs 
Na+- K+ activity. This enzyme is responsible for rapidly correcting Na+ and K+ levels following 
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an action potential but in these conditions, it does not work properly because of a 
pathological increase in intra-axonal Na+ concentrations. As a consequence, there is the 
involvement of Na+-Ca2+ pumps that, eliminating Na+, increases intracellular Ca2+ levels 
which, in turn, causes severe damages (Franklin and Ffrench-Constant, 2008). 
Besides the formation of myelin sheath, OLs have an important role in maintaining axonal 
integrity and in promoting neuronal growth by synthetizing neurotrophic factors such as 
CNTF, IGF and glial cell-derived neurotrophic factor (GNDF) (Dai et al., 2001; Du and 
Dreyfus, 2002). 
Since it seems clear that a damage to myelin and OLs has direct consequences on neurons 
and, in general, on the entire CNS, it is important to understand the causes of 
demyelination. 
One of the most frequent causes of OL death or dysfunction is oxidative injury. A toxic 
byproduct of ATP synthesis is hydrogen peroxide, which, if not metabolized, has been 
shown in vitro to cause DNA degradation and OL apoptosis. Cellular metabolism also creates 
reactive oxygen species, which are highly toxic and induce lipid peroxidation and DNA 
damage (McTigue and Tripathi, 2008). Moreover, paradoxically, OLs have low 
concentrations of glutathione (GSH), a robust antioxidative enzyme. This low glutathione 
concentration would allow intracellular iron levels rise. If these defenses are not able to 
keep reactive oxygen species (ROS) levels under the threshold of toxicity, there will be 
oxidative stress. The oxidative stress is a common feature of many pathological conditions 
as MS, Alzheimer’s disease, spinal cord injury, CNS hypoxia and ischemia (Stankiewicz et 
al., 2007; McTigue and Tripathi, 2008). 
Excitotoxicity is another important cause of OL death. It is the pathological process by 
which nerve cells are damaged and killed by excessive stimulation by neurotransmitters 
such as glutamate and similar substances. This occurs when receptors for the excitatory 
neurotransmitter glutamate (glutamate receptors) such as the NMDA receptor and AMPA 
receptor are over-activated by glutamatergic storm. Excitotoxins like NMDA and kainic acid, 
which bind to these receptors, as well as pathologically high levels of glutamate, can cause 
excitotoxicity by allowing high levels of Ca2+ ions to enter the cell. Ca2+ influx into cells 
activates a number of enzymes, including phospholipases, endonucleases, and proteases 
such as calpain. These enzymes go on to damage cell structures, degrade cytoskeletal 
proteins and cause mitochondrial disruption leading to reactive oxygen species production 
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and cytochrome c release. Glutamate release may be a consequence of a trauma or anoxia, 
which invert the direction of transporters or may be secreted by microglia and 
macrophages, exchanging glutamate with cysteine. It has also been demonstrated that 
immature OL can release glutamate via reverse glutamate transport, which can then 
feedback and damage the cells through calcium influx (McTigue and Tripathi, 2008).   
The loss of OLs and of the myelin sheath has dramatic consequences in the CNS but in some 
particular conditions, our organism is able to face this pathological process and plays out a 
reparative response called remyelination. During this process, the entire myelin sheaths are 
restored to demyelinated axons, saltatory conduction is reinstated and functional deficits 
are resolved. Remyelination is a spontaneous process to the myelin damage but, the new 
myelin sheath, although functional, is shorter and thinner than the original one. For this 
reason, it is believed that the mechanism of remyelination is essentially different to that of 
myelination. One hypothesis of this difference is that, while the myelinating OL associates 
with a dynamically changing axon, that is yet to achieve its full length and diameter, the	
remyelinating OL engages an axon that is undergoing less change, having already reached 
its mature size. Therefore, the remyelinating OL is not subjected to the same degree of 
dynamic changes as the myelinating OL during development. Such changes may, by analogy 
with other cell types, regulate protein synthesis and a number of intracellular signaling 
pathways and make an essential contribution to the elaboration of the normal myelin 
sheath (Franklin and Ffrench-Constant, 2008). 
Remyelination follows the steps listed below: 
1. Generation of new OPCs 
2. Migration of OPCs in the demyelinated area 
3. Axon engagement and OPC differentiation 
4. Formation of a new myelin sheath 
All the steps listed before are in common to the myelination process, but the question 
where new OLs come from has been a central theme of remyelination research over several 
decades. Now, it is believed that in most cases remyelination is mediated by new OLs 
derived from a population of adult OPCs. These proliferating cells are also known as NG2+-
cells, based on the expression of the membrane chondroitin sulphate proteoglycan NG2 or 
polydendrocytes to reflect their multi-processed morphology and their lineal relationship to 
OLs. These cells represent 5-8% of the cell population and are dispersed in both white and 
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grey matter in various CNS regions and in the subventricular zone (SVZ). These precursors 
remain in the adult brain in a quiescent state and are able to proliferate and migrate, even 
if less rapidly, towards demyelinated areas (Franklin and Ffrench-Constant, 2008). Previous 
time-lapse imaging revealed how NG2+ cells are recruited to sites of focal CNS injury and 
rapidly migrate and proliferate to restore their density (Hughes et al., 2013). Indeed, NG2 
is a core organizer of Rho GTPase activity and localization in the cell, which controls OPC 
polarity and directional migration (Binamè et al., 2013). 
Of note, during the first phases of demyelination, all the neural cells of the damaged area 
are involved in this process in particular microglia/macrophages and astrocytes which are 
immediately activated and start releasing different factors that are essential for the 
beginning of remyelination.  
Among these, PDGF and FGF have been found over-expressed after demyelination (Hinks 
and Franklin, 1999) and some others are the same involved in the embryonic OPC 
development. For example, FGF and IGF1 have an important role in the inhibition of OLs 
differentiation but they are responsible of OPC recruitment during remyelination and 
regulate their transition towards a mature phenotype. 
Following recruitment, the OPCs differentiate into remyelinating OLs. This differentiation 
phase encompasses three distinct steps: establishing contact with the axon that is to be 
remyelinated, expressing myelin genes and generating a myelin membrane, and finally 
wrapping and compacting the membrane to form the sheath. Interestingly, in recent years, 
several studies have provided compelling evidence for a key role of neuroinflammation in 
re-myelination. As previously mentioned, microglia and macrophages, as said before, are 
present within the sclerotic plaques typical of the demyelinating diseases and within the 
inflammatory lesions of neurodegenerative diseases. Even though it is believed that 
inflammatory factors, proteases and chemical mediators released from these cells 
contribute to worsen the primary lesions by determining the onset of a secondary neuronal 
damage, now scientific community has accepted that the microglia activation does not 
always produce a deleterious effect in CNS. In fact, their main function is to infiltrate the 
damaged area to phagocytize cellular debris, apoptotic cells and pathogens participating in 
this way to the reparative mechanisms. Furthermore, microglia and macrophages can 
counteract cerebral lesions by releasing inflammatory and neurotrophic cytokines and 
immunosuppressive factors which are able to promote neuronal tissue growth. However, re-
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myelination does not always properly occur. The efficiency of re-myelination is affected by 
the non disease-related factors age, sex and genetic background. These generic factors will 
have a bearing on the efficiency of re-myelination regardless of the disease process that is 
involved (Franklin, 2002). 
Like all regenerative processes, the efficiency of re-myelination decreases with age. This 
manifests as a decrease in the rate at which it occurs and is likely to have a profound 
influence on disease progression (which, in the case of MS, can occur over many decades). 
The consequences of slow re-myelination are compounded by an age-associated increase in 
the vulnerability of demyelinated axons to atrophy. The age-associated effects on 
remyelination are due to a decrease in the efficiency of both OPC recruitment and OPC 
differentiation. Moreover, during aging the production of cytokines, chemokines and growth 
factors diminishes (Franklin and Ffrench-Constant, 2008; Franklin and Kotter, 2008). 
In addition to these generic factors, remyelination could also be incomplete or fail for 
disease specific reasons. This may be related to a primary deficiency in precursor cells or to 
a failure of precursor cell differentiation and maturation (Franklin and Ffrench-Constant, 
2008). 
It is clear that, in order to stimulate remyelination, it would be important to increase the 
knowledge on this issue and try to answer many of the still unresolved questions. 
2.3.2	OPCs	contribute	to	glial	scar	formation	
After any kind of CNS injury, glial cells become activated and orchestrate the formation of 
the glial scar. The glial scar is characterized by a high content of extracellularmatrix (ECM) 
molecules forming an environment known to block axonal regeneration and remyelination 
(Cregg et al., 2014; Silver and Miller, 2004). While reactive astrocytes are the principal 
cells present within the glial scar, it is now clear that OPC are not only bystanders during 
scar formation. Following spinal cord injury, OPCs proliferate and upregulate NG2 
expression, thereby inhibiting axonal regeneration (Tan et al., 2005). Rhodes et al. 
reported that treatment with antimitotic drugs, aimed at diminishing glial scar formation 
by eliminating OPC proliferation in knife wound injuries, results in a slight improvement in 
axonal regeneration (Rhodes et al., 2003). This result suggests that OPC proliferation and 
upregulation of NG2 can be detrimental to axon regrowth. Conversely, OPC expression of 
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NG2 has also been shown to support axon growth in vitro, even when NG2 was 
overexpressed in OPCs (Yang et al., 2006).  
Chondroitin sulfate proteoglycans (CSPGs) are a key component of the inhibitory glial scar 
(Davies et al., 1997; Lau et al., 2012) and it have been show that OPCs also produce 
keratan sulfate proteoglycan after injury, and also neurocan and versican but CSPGs are 
known to impair CNS repair (Asher et al., 2000, 2002; Jones and Tuszynski, 2002). In 
conclusion, OPCs clearly participate in the formation of the glial scar and produce CSPGs 
that impair CNS repair and their differentiation into mature myelinating OL. This apparent 
duality in function clearly highlights the multi-functionality of OPC in the CNS (Fernandez-
Castaneda et al., 2016). 
	
2.3.3	OPCs	as	innate	immune	cells	
Microglia and astrocytes are considered to be the classic innate immune cells of the CNS 
because of their response to pathogens or tissue damage and their ability to recruit 
peripheral immune cells (Ransohoff and Brown, 2012). However, the literature contains 
evidence that OPCs are not simple spectators of the CNS immune response. In a mouse 
model of cerebral prolonged hypoperfusion, OPCs are the initial producers of MMP9, an 
enzyme necessary for degradation of the extracellular matrix, prior to the appearance of 
white matter damage (Seo et al., 2013). Furthermore, authors demonstrated that OPC 
derived MMP9 could mediate the opening of the BBB and the infiltration of neutrophils that 
ultimately damage the myelin sheath in this model (Seo et al., 2013). Moyon et al. have 
recently demonstrated that OPCs isolated from the brain of mice undergoing cuprizone-
induced demyelination express high levels of CCL-2 and IL-1β (Moyon et al., 2015). CCL-2 
has a critical role in recruiting monocytes (Deshmane et al., 2009), while IL-1β is a 
powerful inflammatory cytokine involved in many aspects of the immune response (Sims 
and Smith, 2010). While authors did not explore the role of these mediators on immune cell 
recruitment/ activation, they discovered that CCL-2 promotes OPC migration in vivo and is 
also expressed by OPCs present in active multiple sclerosis (MS) lesions (Moyon et al., 
2015). Recent work by Gadani et al. also highlights the role that myelinating glia play in 
repair after spinal cord injury. Oligodendrocytes release IL-33, a nuclear alarmin implicated 
in orchestrating the recruitment of peripheral immune cells necessary for CNS repair 
(Gadani et al., 2015). Although predominantly expressed by oligodendrocytes, OPCs also 
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express IL-33 and may participate in promoting CNS repair (Gadani et al., 2015b). Beyond 
producing inflammatory mediators, OPC can respond to cytokines and chemokines, such as 
TNF-α IL-1β and IFN-γ (Moore et al., 2016; Arnett et al., 2001; Vela et al., 2002). The 
impact of these molecules on OPCs remains controversial, with reports suggesting both a 
beneficial outcome on myelination and induction of OPC death. For example, TNFα is highly 
expressed in demyelinating MS lesions and has been shown to potentiate IFN-γ-induced cell 
death in vitro (Andrews et al., 1998; Watzlawik et al., 2010). Arnett et al. showed a modest 
delay in cuprizone-induced oligodendrocyte death in TNF-α knockout mice, implicating it as 
a potentially harmful cytokine (Arnett et al., 2001). Unexpectedly, the study also showed 
that TNF-α knockout mice suffered from impaired remyelination (Arnett et al., 2001). Mice 
lacking TNF-α showed decreased decreased OPC proliferation and, as a result, less 
oligodendrocytes were ultimately generated, accounting for decreased remyelination 
(Arnett et al., 2001). This data implies that TNF-α has a dual role in both demyelination and 
remyelination.  
A recent study with a TNF receptor 2 (TNFR2) conditional KO mice, with selective TNFR2 
ablation in oligodendrocytes, provided an evidence for TNFR2 as an important signal for 
oligodendrocyte differentiation. They demonstrated that oligodendroglial TNFR2 is a key 
mediator of tmTNF-dependent protection in EAE. In fact, following activation by 
transmembrane TNF, TNFR2 initiates pathways that drive oligodendrocytes into a 
reparative mode contributing to remyelination following disease (Madesen et al., 2016).  
Furthermore, another study demonstrated that OPCs respond to the T cell produced 
cytokine, IL-17, and actively participate in the amplification of pathology in EAE (Kang et 
al., 2013b). Finally, OPCs have been shown to be phagocytic in vitro, as isolated cultures of 
OPCs can efficiently engulf myelin debris (Gaultier et al., 2009). Further investigation 
should be performed in vivo to determine if OPC could participate in the clearance of 
cellular debris in vivo, during CNS diseases, especially considering their rapid recruitment 
at the injury site. In conclusion, OPCs also contribute to the immune response in the CNS by 
producing and responding to inflammatory mediators in a multitude of pathologies 
(Fernandez-Castaneda et al., 2016).  
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Chapter	3		
The	G	protein	coupled	receptor	GPR17	
	
3.1		Identification	and	gene	cloning	
GPR17 is a G-protein coupled receptor (GPCR) that was first identified thanks to a screening 
of a human cDNA library for P2Y-receptor homologous sequences (Blasius et al, 1998). Two 
distinct transcripts of the human GPR17 receptor (hGPR17) were identified to be generated 
by alternative polyadenylation, resulting in the generation of two different isoforms lately 
named short (hGPR17-S) and long isoform (hGPR17-L) (Pugliese et al., 2009; Benned- Jensen 
and Rosenkilde, 2010). Subsequently also the rat and mouse GPR17 orthologues were 
identified and cloned, showing 80% homology in the amino acid sequence to the hGPR17 
(Ciana et al., 2006; Lecca et al., 2008). 
The expression pattern and functional characterization of GPR17 have been studied since 
few years, and our knowledge is therefore based on few in vitro studies on the hGPR17, and 
several in vitro and in vivo studies for the rGPR17 and mGPR17 (rat and mouse GPRI7) but 
there is an increasing interest for this peculiar receptor due to its strategic time-restricted 
expression during oligodendrogenesis. 
Here, the main structural, pharmacological, functional characteristics and expression 
profiles of GPR17 receptor so far known are reported. 
Although GPR17 amino acidic sequence is conserved among species, the gene structure is 
pretty different. The hGpr17 gene is indeed located on chromosome 2 and it is composed of 
four exons, of which only two contain coding sequences. The rat and mouse Gpr17 gene are 
both located on chromosome 18. rat Gpr17 (rGpr17) is composed only by one exon, whereas 
the mGpr17 (mouse Gprl7) has two different exons and only a small portion of the second 
exon encodes for the GPR17 protein.  
3.2	GPR17,	a	promiscous	receptor:	structure	and	pharmacological	properties	
The receptor is named GPR17 because before its endogenous ligands were described, it was 
classified as an orphan GPCR, since it displayed the same structure of G protein coupled 
receptors, with 399 amino acids including 7 transmembrane domains, an N- and a C-
terminus (Ciana et al., 2006; Lecca et al., 2008). As already mentioned, GPR17 structure is 
phylogenetically related to two classes of GPCR receptors: P2Y receptors and CysLT 
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receptors (Figure 3.1). The former class of receptors (P2Y receptors) includes P2Y1, 2, 4, 6, 
11,12,13,14, that respond to adenine nucleotides (ATP adenosine-5 '-triphosphate and ADP 
adenosine monophoshate), uracil nucleotides (UTP uridine triphosphate and UDP uridine 
diphosphate) and sugar nucleotides (UDP-glucose and UDP-galactose). CysLT receptors, 
namely CysLT1 and CysLT2, are also a class of GPCRs responding solely to cystenil- 
leukotrienes such as LTD4, LTC4 and LTE4. Initially, GPR17 showed pharmacological 
responses to both classes of ligands, therefore it has been one of the first GPCRs to be 
classified as a "hybrid" or "dual" receptor (Ciana et al, 2006; Parravicini et al, 2008); 
recently, it has been demonstrated that GPR17 is a promiscous receptor and new ligands 
have been identified. 
	
Figure	3.1	–	Phylogenetic	tree	that	represents	the	relationship	between	GPR17	and	P2Y	and	CysLT	receptors	(from	Ciana	et	
al.,	2006)	
3.2.1	GPR17	agonists	
In the last few years, many studies have been performed in order to clarify the 
pharmacological profile of this receptor. To find the natural ligands of GPR17, the cDNA of 
the short form of the human receptor was cloned in an expression vector pcDNA3.1, that 
was transfected in 1321N1 cells, COS-7 and HEK-293. [35S]GTPγS binding studies showed that 
in 1321N1 cells, which do not express functional P2Y receptors (Communi et al., 1999), the 
expression of GPR17 induces concentration-dependent responses to LTC4 and LTD4 (with 
LTC4>>LTD4) and UDP, UDP-glucose and UDP-galactose (with UDP- galactose=UDP>UDP-
glucose ), whereas no responses were identified for ligands as ATP, ADP, 2-methyl-thio-
ADP, UTP, α,β-methylene-ATP and guanosine (Ciana et al., 2006). 
Moreover, additional studies conducted in 1321N1 cells expressing the GPR17 receptor 
demonstrated that prolonged exposure of these cells to agonists UDP-glucose and LTD4 
determines the desensitization of the receptor, followed by a process of resensitization 
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consequent to the removal of agonists (Daniele et al., 2011). More recently, GPR17 has 
been reported to also respond to emergency signals signals like oxysterols, in a similar way 
to other related receptors involved in inflammatory	responses (like EB2 and CXCR2) (Sensi 
et al., 2014) and to the chemokine SDF-1 (stromal derived factor-1 or CXCL12) that can 
specifically activate GPR17; it has been also demonstrated that cangrelor, a GPR17 
orthosteric antagonist, can block the SDF-1-mediated activation of GPR17 in a 
concentration-dependent manner (Parravicini et al., 2016).  
Pharmacological studies were conducted also on the rodent GPR17 receptor. The 
pharmacology of the rat GPR17 (rGPR17) is identical to that of human as regards the type 
of agonists, but shows variations in the order of the potency (LTD4>LTC4; UDP -
glucose>UDP, and UDP-galactose has no effect). On the contrary, from the pharmacological 
studies conducted on the murine receptor emerges that the mouse GPR17 (mGPR17) has a 
pharmacological profile more similar to that of the human receptor (UDP>UDP - 
galactose>UDP-glucose; LTE4>LTD4>LTC4) (Lecca et al., 2008). Transfection of GPR17 in 
other cell lines such as COS-7, HEK-293 and CHO confirmed the results obtained in 1321N1 
cells (Ciana et al., 2006). 
It is interesting to emphasize that the EC50 values of the tested agonists are in agreement 
with the known characteristics of the P2Y receptors (micromolar, µM) and for cystenyl- 
leukotrienes; in fact, for the first, the EC50 is comprised in a range while for the cysteinyl- 
leukotrienes (nanomolar). 
The long form of the human GPR17 receptor (hGPR17) was characterized pharmacologically 
too. Similarly to the short form, treatment with both uracil and cysteinyl- leukotrienes 
agonists induces the appearance of concentration-dependent responses to LTC4 and LTD4 
(with LTC4 >LTD4) and also to UDP, UDP-glucose (UDP-glucose) and UDP- galactose (with 
UDP-galactose=UDP>UDP-glucose). However, while the values found for the cysteinyl-
leukotrienes not show significant differences with those described for the short form, UDP-
glucose appears to be slightly more potent on the long form (Pugliese et al., 2009). One 
explanation for these differences has been given by recent studies of molecular dynamics 
simulation on the short form of the receptor. These studies suggest that, in addition to an 
inner pocket for the binding of the nucleotides, GPR17 has an accessory site in a region 
formed by three extracellular domains (EL): EL2, EL3, and the N-terminal sequence. This 
binding site could drive small extracellular agonists towards the main inner binding site, 
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leading to receptor activation (Parravicini et al., 2008; 2010). Even though, modeling 
studies on the long form of the receptor have not yet been described, it is thought that the 
N-terminal sequence longer 28 amino acids than the long ones, might change the 
conformation of this accessory binding site, influencing the	 affinity	 of	 nucleotide agonists 
(Pugliese et al., 2009), thus explaining the observed differences between the two isoforms. 
Similar to these studies, the group of Benned-Jensen has performed experiments in 
transfected HEK293 cells, demonstrating that the ligands UDP, UDP-glucose and UDP- 
galactose activate the two isoforms of the receptor GPR17, with more power on the long 
ones. Contrary to the above mentioned studies, they did not find receptor activation by 
cystenil- leukotrienes, LTD4 and LTE4 (Benned-Jensen and Rosenkilde, 2010; Nörregaard et 
al., 2011). 
However, recent results in recombinant in vitro systems suggest that the GPR17 receptor 
may also act through a ligand-independent way. It appears that GPR17 behaves as a 
negative allosteric modulator of the CysLT1 receptor, that is able to respond to LTD4, 
through the formation of a dimer receptor-receptor. This action of GPR17 does not seem to 
be due to its activation by endogenous ligands (Maekawa et al., 2009). 
In contrast with these results, the group of Qi demonstrated that, in C6 and CHO cells 
stabling expressing GPR17, neither UDP, UDP sugars, nor cysteinyl-leukotrienes activate 
GPR17 (Qi et al., 2013). The reasons for the discrepancies between the results obtained by 
different laboratories still remain to be clarified. 
3.2.2	GPR17	antagonists	
In the studies aimed at characterizing GPR17 pharmacological profile, the activity of some 
known purinergic and cysteinyl-leukotrienes antagonists was also assayed. As for agonists 
also for the antagonists the [35S]GTPγS binding assay was performed in 1321N1 cells 
expressing the receptor (long or short isoform of the human receptor, mouse and rat 
receptor). As nucleotide antagonists both cangrelor (N(6)-(2-methyl-tioetil)-2-(3,3,3-
trifluoropropiltio)- beta,gamma-diclorometilene-ATP), which is known to antagonize P2Y12 
and P2Y13 (Ingall et al., 1999; Marteau et al., 2003; Fumagalli et al., 2004) and MRS2179 
(2'-deoxy-N6-metiladenosina3',5'-bisphosphate) which antagonizes P2Y1 (Jacobson et al. 
2002) were assayed; both molecules inhibit in a concentration-dependent the binding of the 
[35S]GTPγS stimulated by UDP -glucose, with nanomolar IC50 values. 
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It was also demonstrated that a non-hydrolyzable analog of ATP, ATPβS, which does not act 
as an agonist neither on the short nor on the long form of the human receptor (Ciana et al., 
2006), may act as an antagonist in blocking in a concentration-dependent manner the 
activation of GPR17 induced by UDP-glucose and LTD4. The fact that this compound 
behaves as an antagonist is in agreement with the capacity of cangrelor and MRS2179, two 
derivatives of ATP (Abbracchio et al., 2006), to act as antagonists of GPR17. 
As cysteinyl-leukotriene antagonists, montelukast and pranlukast were assayed (Brink et 
al., 2003; Capra et al., 2006). Both these two compounds inhibit the activation induced by 
LTD4 of human, rat and mouse receptor, with values nanomolar IC50 typical of CysLT1. 
Due to the dual nature of this receptor, it was therefore hypothesized the existence of two 
distinct binding sites on the receptor: one for nucleotides and one for the cysteinyl- 
leukotrienes. 
3.3	GPR17	expression	pattern	in	the	CNS	
So far the majority of the studies on GPR17 have been performed in rodent models (rats 
and mice). However, the receptor was first identified in a cDNA library from human 
hippocampus (Blasius et al, 1998). The expression of GPR17 in the human brain was lately 
confirmed by mRNA analysis from different human tissues (Ciana et al, 2006). hGPR17 is 
expressed at high levels in organs or tissues that can undergo ischemic damage, namely 
brain, heart and kidney (Ciana et al., 2006). The long form is, instead, expressed 
exclusively in the brain, especially in the cortex and striatum (Pugliese et al., 2009; 
Benned-Jensen and Rosenkilde, 2010). 
Other studies showed GPR17 expression on human and mouse mastocysts and bone marrow 
derived monocytes (Maekawa et al, 2009; Maekawa et al, 2010), where the receptor seems 
to tightly co-localize with CysLTR1. Finally, and most interesting, a trascriptome analysis 
performed on human and mouse adult neural stem cells and fetal embryonic tissue revealed 
expression of the receptor specifically in adult neuroprogenitors (Maisel et al, 2007). 
Concerning the GPR17 expression in the brain, the same pattern of expression observed in 
human has also been confirmed in rats and mice (Ciana et al, 2006; Lecca et al, 2008). In 
fact, immunohistochemistry experiments carried on in our laboratory demonstrated that, in 
rat and mouse brain cortex, GPR17 is expressed by two distinct cell types: 
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• neurons: where it co-localizes with typical neuronal proteins, SMI-311 (neurofilament 
marker), β-tubulin (neuronal specific tubulin) and NeuN (neuronal nuclear protein) 
• numerous cells dispersed in both grey and white matter, displaying small cell bodies with 
fine radiating processes and expressing typical OPC markers, such as NG2 and Olig2. 
No co-localization of GPR17 was found with more mature myelinating oligodendroglial 
markers, such as CNPase, MAG and MBP, suggesting that GPR17 may be expressed at a 
specific stage of oligodendroglial differentiation. 
In mice and rats, GPR17 was never found in astrocytes (no co-localization with GFAP, glial 
fibrillary acidic protein), and in non-activated microglia (no co-localization with Iba) 
assuming therefore that the receptor is not localized in these cell types (Lecca et al., 
2008). GPR17 is instead co-expressed with the marker IB4 in activated microglia (Lecca et 
al., 2008). 
Recently, the first characterization of GPR17 expression in neurosurgical and autoptic 
samples from patients with traumatic brain injury (TBI) has been published. In this study 
through immunohistochemistry analysis it has been demonstrated that GPR17 co-localizes 
with various specific markers of brain cells. Specifically, it has been shown that, in the 
damaged area, the receptor is expressed by injured neurons (NeuN+ in post-surgical 
samples; MAP2+ in autoptic samples), by a subpopulation of hypertrophic astrocytes (GFAP+) 
with a stellate morphology, by infiltrating cells that participate in the processes of repair 
engulfing the dead cells, microglia/macrophages (IB4+ tissues in post-surgical samples, Iba1+ 
in autoptic samples), and OPCs (CNPase+ and O4+ in autoptic samples). Furthermore, 
through a spatio- temporal gradient analysis, it was shown that GPR17 expression is very 
strong in cells inside and at the borders of the necrotic core. These cells are activated 
microglia/macrophages; more externally GPR17 is expressed by activated astrocytes. 
Concerning neurons, a reduction of GPR17 expression has been observed as the distance 
from the injured area increased; finally, in the most distal areas, GPR17 is also found in 
ramified cells expressing O4 and CNPase, thus confirming that they are OPCs. These results 
confirm the findings from the studies in rodents concerning the distribution of the receptor 
in the damaged brain and its involvement in repair processes (Franke et al., 2013).  	
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3.4	Transduction	signaling	pathways	activated	by	GPR17	
Studies on the system of signal transduction showed that, in cells transfected with GPR17, 
the receptor is mainly coupled to Gi protein that inhibits the activity of the enzyme 
adenylate cyclase and consequently the formation of cAMP (Ciana et al., 2006). It was also 
demonstrated the activation of Gq protein which, in turn, induce the activation of 
phospholipase C (PLC) and the increase of intracellular calcium levels. However, this 
transduction system does not seem to represent the main signaling pathway used by the 
receptor, as only 30% of the cells transfected with GPR17 is able to couple to PLC (Ciana et 
al., 2006). 
Similarly, studies carry on in rat primary OPCs, which express physiologically GPR17 during 
a specific temporal window of their differentiation process (see paragraph 2.1.2), 
confirmed that this receptor is coupled to Gi and that its activation after the exposure to 
GPR17 agonists reduces cAMP levels (Fumagalli et al., 2011). Furthermore, the siRNA-
induced GPR17 knock-down supports the hypothesis that the effects on cAMP levels 
observed after treatment with GPR17 agonists are specifically mediated by this receptor: in 
fact, they are completely obliterated in GPR17-silenced cells. No effect on the calcium 
intracellular levels was observed after GPR17 agonists exposure in primary OPCs, suggesting 
that, in this native system, GPR17 is not associated with protein-Gq (Fumagalli et al., 2011). 
It has also been demonstrated by electrophysiological studies in 1321N1 cells stably 
expressing the hGPR17 that the activation of the receptor with micromolar concentrations 
of UDP, UDP-glucose and UDP-galactose and with nanomolar of LTD4 leads to an increase of 
the outward potassium currents while the treatment with MRS2179, specific antagonist for 
P2Y1, but also active on GPR17, blocks this effect (Pugliese et al., 2009). It seems that the 
effect observed is due to the activation of large-conductance, Ca2+-activated BK (or maxi-K) 
potassium channels widely expressed in human glioma cells (Basrai et al., 2002). These ion 
channels react to increases in intracellular Ca2+ and membrane depolarization, which follow 
an acute ischemic stroke, by increasing K+ efflux, rapidly hyperpolarizing the membrane 
and reducing further voltage-dependent Ca2+ influx (Gribkoff et al., 2001). 
More recently, it has been demonstrated that, after the immature oligodendrocyte stage, 
to enable cells to complete maturation, GPR17 is physiologically down-regulated via 
phosphorylation/desensitization by G protein-coupled receptor kinases (GRKs); conversely, 
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GRKs are regulated by the "mammalian target of rapamycin" mTOR. However, how GRKs 
and mTOR are connected to each other in modulating GPR17 function and 
oligodendrogenesis has remained elusive. Fumalli and co-workers showed that, in maturing 
OPCs, both rapamycin and Nutlin-3, a small molecule inhibitor of Mdm2-p53 interactions, 
increased GRK2 sequestration by Mdm2, leading to impaired GPR17 down-regulation and 
OPC maturation block (Fumagalli et al., 2015). 
	
3.5	GPR17	function		
	
Studies aimed at understanding GPR17 function have been performed in two tissues: the 
CNS (brain and spinal cord) and the immune-system (Ceruti et al, 2011; Ciana et al, 2006; 
Lecca et al, 2008; Maekawa et al, 2010; Mao et al., 2013). Only one study has been 
published on the modulation of the immune response to allergenes by GPR17 activation 
(Maekawa et al, 2010). As previously mentioned GPR17 is co-expressed on dendritic cells 
together with CysLTR1. In case of forced allergene (dust) exposure, GPR17 seems to 
negatively modulate the response of CysLTR1-mediated inflammatory cell accumulation. 
This observation opens the possibility to use GPR17 ligands to positively modulate the 
immune reaction to allergenes. 
On the other hand, more numerous are the studies aimed at understanding GPR17 function 
in the CNS. GPRl7 therapeutic potential was first assessed in a rat model, and subsequently 
in a mouse model, of ischemia (MCAo, medial cerebral artery occlusion) (Ciana et al, 2006; 
Lecca et al, 2008). rGPR17 was shown to be expressed in neurons, OPCs and in microglial 
cells upon pathological condition. The application of a P2Y antagonist and more specifically 
the use of anti-sense oligonucleotide targeting GPR17 are sufficient to reduce the 
penumbra area of the ischemic damage. It is not clear, however, if the ischemic damage 
reduction is due mainly to the effect on a specific cell type or if it was more general. 
Therefore, in this case GPR17 appears to be pro-inflammatory and its blockage, with the 
antagonist and anti-sense oligonucleotide, improves functional recovery (Ciana et al, 2006; 
Lecca et al, 2008). 
Use of the anti-sense oligonucleotide, gave positive results in terms of damage reduction 
and functional recovery also in a model of spinal cord injury (SCI), again suggesting an 
active role of GPR17 in damage propagation (Ceruti et al, 2009). In this scenario the 
	 67	
function of GPR17 was described to be temporal and cellular specific; the first response to 
injury provokes neuronal and OL death through GPR17 activation; later, the recruitment of 
microglia and GPR17+-macrophages seems to shed the first steps of tissue remodeling and 
repair, that was followed by the up-regulation of GFAP, as a marker of stem-cell like 
properties, on GPR17 positive ependymal cells. The multiplicity of roles exploited by GPR17 
in the SCI model can be explained by the diverse actions that its endogenous ligands, 
abundantly released during injury, may play. 
In a similar way, acute damage to myelin induced by lysolecithin injection in corpus 
callosum induced a strong over- expression of GPR17 at the lesion site 10 days after injury 
(Boda et al., 2011). 
The fact that GPR17 may act as sensor for WM damage has also been confirmed in an 
animal model of periventricular leukomalacia (PVL), that is the most common ischemic 
brain injury in premature infants. In this work, it has been shown that GPR17+-glial 
progenitor cells, within the white matter, together with the progenitors cells of the SVZ, 
are significantly increased after an ischemic event and migrate towards the lesion to 
support its repair. However, the endogenous self-repair capacity of these cells appear to be 
limited, since the more mature OLs do not completely recover from experimental ischemia. 
This limitation is likely associated with cerebral microenvironmental factors, such as 
ischemia-induced intracellular calcium overload, excitotoxicity caused by overstimulation 
or secondary effects from over-expression of certain immediate-early genes (Mao et al., 
2013). 
In line with these findings, treatment of highly proliferating neurospheres from murine 
oligodendroglioma cells with UDP-glucose, UDP or LTD4 reduced proliferation and expanded 
the pool of Olig2+ OLs, suggesting that GPR17 activation directs cells to differentiation 
(Dougherty et al., 2012). 
Taken together the data described above suggest that GPR17 represents an interesting 
target to develop new approaches to foster tissue repair in different pathological 
conditions. 
3.5.1	Role	of	GPR17	in	OL	differentiation	
In 2009, Chen and colleagues demonstrated, through a chromatin immunoprecipitation 
(ChIP), that the transcription factor Olig1 can directly bind to the promoter of GPR17 and 
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regulates it negatively. Accordingly, GPR17 was also identified as one of the genes down-
regulated in Olig1 mutant mice (Chen et al., 2009). In this work, GPR17 has been proposed 
as a negative regulator of the OPC differentiation. Both in vitro and in vivo (using a mouse 
model) it has been demonstrated that GPR17 over-expression blocks OPC maturation and, in 
some cases, induces death. In fact, although the precursors are properly generated, they 
are not able to proceed in the differentiation process and, as a consequence, there is a 
defective myelinogenesis and hypomyelination (Chen et al., 2009). 
In vitro studies in rat postnatal OPC cultures, showed that GPR17 expression labels a 
specific temporal window of OL differentiation process. Specifically, during the early stages 
of differentiation, GPR17 receptor decorates two subsets of slowly proliferating cells. The 
former corresponds to early, morphologically immature slowly proliferating NG2+ precursor 
cells that also express Olig2, PDGFRα, and the immature PLP isoform DM-20; the latter 
corresponds to more ramified, still immature pre-oligodendrocytes that are losing NG2 and 
PDGFRα immunoreactivity and already express O4, O1, and the two splicing variants of the 
myelin protein PLP. After this differentiation stage, GPR17 expression is progressively 
turned down, and the GPR17 protein is never found in fully mature MAG+ or MBP+ OLs 
(Fumagalli et al., 2011). 
In this cells, it has been demonstrated that GPR17 receptor has a functional role during the 
differentiation process; in fact, its activation by UDP-glucose (100 µM) or LTD4 (100 nM) for 
72 hours, induced a significant increase in the number of MBP+-cells (Lecca et al., 2008; 
Fumagalli et al., 2011). Additional in vitro data also showed that, GPR17 antagonists (for 
example, cangrelor) or knock-down by siRNAs impaired the normal differentiation program 
of OPCs (Fumagalli et al., 2011). These data suggest that GPR17 may be involved in the 
control of the transition from OPCs to mature myelinating OLs enabling the repair or 
damaged myelin. 
In support to these data, recent studies have also shown that GPR17 activation by UDP- 
glucose enhances delayed rectifier K+ currents without affecting transient K+ conductances. 
This effect was observed in a subpopulation of OPCs (NG2+) and immature pre-OL (O4+) 
whereas it was absent in mature OLs, in line with GPR17 expression, that peaks at 
intermediate phases of OL differentiation and is thereafter down-regulated to allow 
terminal maturation. The effect of UDP-glucose on K+ currents is concentration-dependent, 
blocked by the GPR17 antagonists MRS2179 and cangrelor, and sensitive to the K+ channel 
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blocker tetraethyl-ammonium (TEA), which also inhibits OL maturation. Moreover, the 
effect observed parallels the expression of distinct voltage-dependent currents during OPC 
differentiation. In fact, while in OPC progenitors most currents are represented by outward 
rectifying conductances (Ik), in mature OL inwardly rectifying currents (Kir) prevail. 
Altogether these data suggest the enhancement of IK currents after UDP-glucose exposure 
is responsible for the GPR17-mediated facilitating effect in OPC maturation (Coppi et al., 
2013). It was also observed that the receptor has a different intracellular localization 
depending on the differentiation stage: during the first day in culture, it was present within 
the compartments of synthesis of OPCs, while in more advanced differentiation stages it 
was found on the cell surface and within the endosomal compartments. This observation 
suggests that the subcellular distribution of GPR17 is linked to the maturation of these 
cells. In this regard, an in vitro study in Oli-neu cells, an immortalized OPC cell line, 
showed that the exposure to UDP-glucose and LTD4 induces GPR17 internalization, which is 
delivered into early endosomes and sorted either to lysosomes for degradation or recycled 
to the cell surface via small G-protein Rab4-dependent pathway. GPR17 down-regulation is 
the results of these two processes and it seems to be a key event to allow OPCs to proceed 
to myelination (Fratangeli et al., 2013). 
In astrocyte-OPC mixed cultures, it has been demonstrated that the expression of GPR17 
receptor is markedly influenced by culturing conditions (Ceruti et al., 2011). In the 
presence of growth factors (GFs), no significant GPR17 expression is found. On the 
contrary, when cultures are shifted to a differentiating medium, a dramatic, time-
dependent increase in the number of highly branched GPR17+-cells is observed. Under these 
conditions, GPR17 is induced in the totality of O4+-immature OLs. In the same work, it was 
also shown that the addition of ATP to the culture medium without GFs induces cell death, 
suggesting that GPR17 act as danger signal in the presence of high extracellular ATP 
concentrations. The influence of culturing conditions on GPR17 receptor was also 
demonstrated in Oli-neu cells line, in which the expression of the receptor is increased by 
factors released from neurons and astrocytes (Fratangeli et al, 2013). 
An in vivo study has shown that, in cerebral cortex, during mouse brain development, 
GPR17 expression in the oligodendroglial lineage precedes the production of myelin. 
Immediately after birth, the receptor is not expressed, but it progressively appears in an 
increasing fraction of OPCs that stop proliferating and start differentiating up to covering 
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the majority of immature OLs (Boda et al., 2011). Similarly to what observed during the 
development in the rodent cerebral cortex, GPR17 expression begins to be detectable soon 
after birth within the spines and gradually increases until P14. Subsequently, it undergoes a 
strong decline, in parallel with the beginning of myelinogenesis. Finally, according to Chen 
and co-workers, GPR17 prevents OPC differentiation allowing the translocation into the 
nucleus of transcription factors that act as potent repressors OPC differentiation: ID2 and 
ID4. In line with these findings, in vitro studies showed an over- expression of ID2 in 
proliferating OPCs, in which the differentiation is slowed or stopped; the levels of this 
repressor are instead reduced during OPC maturation towards mature myelinating OLs. It is 
known that these repressors are able to translocate into the nucleus by passive diffusion 
thanks to their small size, but during OPC differentiation, they are internalized in this 
compartment through an active transport mechanism. Once inside the nucleus, they form a 
complex with Olig1/2 and E47, so that they prevent these factors to bind DNA, resulting in 
inhibition of OPC differentiation. On the contrary, during OPC differentiation, ID2 is found 
in the cytoplasm associated with Enigma Homolog (ENH), a cytoskeletal protein, thus 
allowing Olig1/2 and E47 to bind DNA and to induce the transcription of myelin genes. 
Specifically, Olig1 represses GPR17 thus promoting OPC maturation (Kondo and Raff, 2000; 
Wang et al., 2001; Chen et al., 2009; 2012). It has to be highlighted that, in the GPR17 
over-expressing mice used in this work, GPR17 expression is under the control of the CNP1 
promoter (Chen et al., 2009). As mentioned above, our studies suggest that, GPR17 levels 
are strongly reduced when CNPase starts appearing in immature OLs. Thus, GPR17 forced 
expression at this stage of differentiation, could seriously affect and compromise the 
oligodendrogliogenesis, making this animal model highly contestable. However, these data 
demonstrate a close relationship between GPR17 and the myelination process, suggesting a 
possible role of this receptor in demyelinating diseases.	
3.5.2	GPR17	alterations	in	demyelinating	diseases		
GPR17 is abnormally upregulated in neurodegenerative conditions characterized by myelin 
disruption, independently of the original cause. In fact, it was observed that, both in 
patients with MS and in EAE mice, GPR17 levels are higher compared to controls, and this 
alteration may explained the failure of remyelination observed in this pathological 
conditions (Chen et al., 2009). Furthermore, as described in the previous paragraphs, after 
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a traumatic, ischemic or demyelinating injury GPR17+-OPCs accumulate within the damaged 
area and take part to the reparative processes (Lecca et al., 2008; Ceruti et al., 2009; Boda 
et al., 2011). In contrast with the data described above, in a recent paper, Hennen and co-
workers proposed GPR17 as a negative regulator of myelinogenesis (Hennen et al., 2013). In 
this paper this group claimed that the receptor should be block in order to promote OPC 
maturation. Specifically, they showed that in OPC cultures from heterozygous (GPR17+/−), 
but not homozygous (GPR17−/−) mice, MDL29,951 markedly attenuate the capacity of OLs to 
differentiate suggesting that the addition of GPR17 antagonists to anti-inflammatory drug 
cocktails that are already used in the management of MS may be an innovative strategy to 
promote remyelination (Hennen et al., 2013). 
Despite the conflicting results obtained by different groups within the scientific 
community, GPR17 remains an attractive candidate for the developing of new 
pharmacological compounds. Further studies will clarify whether it will be more useful to 
obtain molecules enabling the activation or the block of this receptor. 
3.6	GPR17	as	a	pharmacological	target	for	MS	
In the last years, the importance of GPR17 as a promising therapeutic target for the 
treatment of neurodegenerative diseases characterized by demyelination and other human 
diseases has been gradually consolidated. The need to have new molecules able to 
modulate the activity of this receptor is an important starting point for improving the 
atomic and molecular knowledge of GPR17. In this respect, the approach of the "drug 
discovery" is a good strategy. 
3.6.1	in	silico	identification	of	new	GPR17	ligands	
In case of receptors such as GPR17 whose molecular structure is still unknown, the 
“homology modeling” is a powerful approach to study ligand-receptor interactions. 
Moreover, in several cases this technique allowed to successfully predict the ligand-
receptor interaction. 
Currently, two homology models of hGPR17 have been built: the first one is entirely based 
on the crystal structure of bovine rhodopsin (bRh), the only high-resolution crystal structure 
of a GPCR available when the model was published. This model allowed to successfully 
predict and characterize the binding site of endogenous ligands and various derivatives of 
GPR17 (Parravicini et al., 2008; 2010; Calleri et al., 2010). Few years later, thanks to 
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protein engineering, a chimeric structure of GPR17 was built (Fig. 3.2) (Eberini et al., 
2011).		
 
Figure	3.2	-Tridimensional	model	of	human	GPR17	receptor.	The	color	spheres	represent	the	binding	site	predicted	for	
extracellular	nucleotides	on	the	receptor.		
Merging the templates of the human adenosine A2A receptor (hA2AR), the human β2-
adrenergic receptor (hβ2AR), the turkey β1-adrenergic receptor (t β1AR) and squid Rh, this 
model was more accurate, allowed the identification of five candidate agonist or partial 
agonist molecules, belonging to very different chemical classes, able to modulate GPR17 
activity with higher potency and efficacy than the endogenous reference compounds. This 
represents the first step towards the rational identification of candidate molecules for the 
development of entirely novel drugs for demyelinating and ischemic diseases, for which no 
effective therapy is yet available (Eberini et al., 2011, see also below). Recently another 
molecule has been proposed as potential agonist of this receptor, the MDL29,951 (Hennen 
et al., 2013). Specifically, using different targeted pharmacological assays (measurement of 
cAMP accumulation, [35S]GTPγS incorporation, inositol phosphate accumulation, Ca2+ 
release, label-free DMR and bioimpedance, and BRET assays), Hennen and co-workers 
demonstrated that in cell transfected with GPR17, stimulus with MDL29,951 is able to 
activate the entire set of intracellular second messengers and their reciprocal cooperation. 
Specifically, through cAMP assay, they showed a dual modulation of the adenylyl cyclase, 
suggesting an engagement of either the Gs and Gi mediated pathways. The coupling to Gi 
subunit after treatment with MDL29,951 was further demonstrated to block the inhibition 
of forskolin-induced cAMP increase with the pertussis toxin (PTX). Moreover, functional 
GPR17-mediated Gαq activity was confirmed by a specific inhibition of Ca2+ flux induced by 
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the agonist. The same effects/responses were not found in control cells, suggesting that 
the activation of the various intracellular cascades is a consequence of the modulation of 
GPR17 induced by the ligand MDL29,951 (Hennen et al., 2013).  
3.7	GPR17	fluorescent	reporter	mouse	line:	GPR17-iCreERT2	
In collaboration with the University of Munich, we generated a novel BAC transgenic mouse 
line that expresses the improved Cre-recombinase (iCre) fused to the modified estrogen 
receptor (iCreERT2, as described in Simon et al., 2012) under the control of the Gpr17 
promoter, and the GFP (green fluorescent protein) under the control of the viral CAG 
promoters (Fig.3.3). This mouse line allowed us to specifically label and monitor the fate of 
GPR17-glia over time without affecting the physiological expression and function of GPR17. 
Indeed, upon tamoxifen administration, thanks to the activity of a Cre recombinase, cells 
expressing GPR17 and their progeny are labeled by GFP, costitutively expressed after 
recombination, thus allowing us to trace their destiny throughout animal’s life (Viganò et 
al., 2015). 
In these mice, Viganò and co-workers found that, under physiological conditions, GPR17+-
cells did not differentiate within 3 months, a peculiarity that was overcome after cerebral 
damage induced by acute injury or ischemia. After these insults, GPR171 NG2-glia rapidly 
reacted to the damage and underwent maturation, suggesting that they represent a 
‘reserve pool’ of adult progenitors maintained for repair purposes (Viganò et al. 2015). 
	
Figure	3.3	-	Generation	of	the	GPR17iCreERT2-GFP	reporter	mouse	line		
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Chapter	4	
Aim	of	the	study	
	
MS is an immune-mediated demyelinating disease of the CNS and it is one of the principal 
causes of neurologic deficit and motor disability in young adults in western countries 
(Ellwardt & Zipp, 2014). MS is characterized by neuroinflammation and demyelinating 
plaques, where myelin is attacked by the immune system (Crawford et al., 2013). Myelin is 
a fundamental component of nerve transmission since it enables impulse saltatory 
conduction from a Ranvier node to another, making nerve transmission faster and more 
efficient compared to unmyelinated fibres.  
Progressive myelin degeneration impairs transmission along nerve fibres in both brain and 
spinal cord (El Waly et al., 2014). 
A number of DMTs are presently available for the treatment of MS and most of them are 
immune-modulatory treatments able to control the clinical course of the disease. Although 
they are proved to reduce the frequency of relapses in MS, they are only effective in about 
50-60% of patients with the relapsing- remitting form of the disease (40-50% of the patients 
are “non-responders”). In a significant percentage of patients (with primary progressive and 
secondary progressive MS) currently available treatments are proved to be ineffective. 
Immune-modulatory treatments target only the immune mediated processes of MS, 
although it has been established that type III and type IV MS subtypes are characterized 
mostly by OL apoptosis and loss, resembling rather a neurodegenerative disease (Denic et 
al., 2011).  
Treating neurodegeneration and halting the progression of disability still remain unmet 
needs. Therefore, there is a paramount need to discover new approaches of treatment for 
the non-immune mediated aspects of MS. 
Two challenges confront us: (i) to develop cocktails of therapies able to shift the immune 
homeostasis of MS patients toward a healthy profile, and (ii) to identify and modulate the 
activity of targets within the neurodegenerative component of MS. 
Re-myelination, the generation of new myelin in the adult nervous system, is an 
endogenous repair mechanism that restores function of denuded axons and delays their 
deterioration. Although re-myelination can be extensive in some patients, in the majority 
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of cases, repair is limited only to the acute phase of disease. A significant current drive in 
new MS therapeutics is to identify targets that can promote re-myelination by boosting 
endogenous OPCs to form new myelin, with the final aim to delay disease progression and 
recover lost neurological functions. 
There are many potential strategies to directly promote myelin repair, and, in this respect, 
the GPCR superfamily is particularly interesting, since it represents the largest class of 
functionally selective drug targets for disease modulation and therapy. GPCRs have been 
studied in great detail in CNS neurons, but have been relatively understudied in glia. In 
recent years, however, exciting new roles for GPCRs in glial cell biology have emerged. 
Here, we focus on the key role of the GPR17 receptor as a regulator of myelinating glial cell 
development, the OPCs, and myelin repair in the most studied animal models of MS and in 
human MS lesions.  
Originally identified as an incomplete sequence of a human GPCR many years ago (Blasius 
et al., 1998), GPR17, a Gi coupled receptor inhibiting cAMP formation, is mainly expressed 
in the CNS, in particular on OPCs (Lecca et al, 2008; Boda et al., 2011, Chen et al., 2009, 
Fumagalli et al., 2011). Since then, much interest on GPR17 has been aimed at 
understanding its function in CNS myelination. 
In vitro experiments demonstrated that early GPR17 silencing profoundly affects OPCs 
ability to generate mature oligodendrocytes, suggesting that, in the absence of this 
receptor, cells are retained at a less differentiated stage and do not progress to maturation 
(Fumagalli et al., 2011). However, interferences with GPR17 physiological downregulation 
at late stages of OPC differentiation also maintained cells at a more immature phenotype 
(Fumagalli et al., 2015). In line with this result, CNP-GPR17 transgenic mice aberrantly and 
un-timely expressing GPR17 in late stage maturing OPCs showed defective myelinogenesis, 
motor disabilities, tremors and precocious death within the second week of life, likely due 
to a disrupted regulation of terminal maturation (Chen et al., 2009). Globally, these 
findings suggest that GPR17 exerts opposite stage-specific roles: a positive role for 
differentiation in early OPCs and a negative function for oligodendroglial maturation in late 
OPCs. They also suggest that, in late OPCs, physiological GPR17 silencing is needed to allow 
cells to complete their maturation program. 
While physiologically GPR17 is mostly an oligodendroglial receptor, within 48 h after acute 
injury, GPR17 is induced, sequentially, in dying neurons inside and at the borders of the 
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ischemic/traumatic lesion, in infiltrating microglia/macrophages and in activated 
parenchymal OPCs in the lesion's surrounding areas, with similar expression patterns in 
different models of disease (Boda et al, 2011, Ceruti et al, 2009, Ciana et al, 2006, Lecca 
et al, 2008, and Zhao et al, 2012). Thus, GPR17 is abnormally upregulated in 
neurodegenerative conditions characterized by myelin disruption, independently of the 
original cause.  
Based on current knowledge on GPR17, it could be hypothesized that, after damage, GPR17 
is initially induced to promote re-myelination and repair; thus, pharmacological 
interventions targeting GPR17 may help to bypass this checkpoint, accomplishing terminal 
maturation and promoting neurorepair. In this respect, GPR17 is an ideal target, since it is 
a membrane receptor that, at variance from other intrinsic regulators of 
oligodendrogenesis, can be easily targeted and manipulated with pharmacological agents.  
On this basis, in order to assess whether this receptor can be proposed as a pharmacological 
target in re-myelinating strategies, the aims of this thesis were: 
1. Determining the physiological mechanisms that regulate GPR17 expression during 
oligodendrogenesis; 
2. Identifying alterations in GPR17 in the most studied animal models of MS; 
3. Testing new pharmacological/biotechnological strategies to correct GPR17 dysfunction in 
MS and resume myelination. 
In particular, we investigated the role of GPR17 in MS pathophysiology through i) its analysis 
in accepted animal models of MS, i.e., EAE and cuprizone models, and ii) its 
characterization in human MS lesions.  
The use of animal models has been necessary to characterize the role of GPR17 in MS 
pathophysiology. Animal models are indeed important to assess the predictivity and 
feasibility of therapeutic approaches directed to new targets, and their appropriate use has 
led to the development of the most recent treatments approved for MS (Kipp et al., 2012). 
For this part of the study, we also took advantage of a new GPR17 transgenic reporter 
mouse line for fate-mapping studies, that allowed us to determine the final destiny of the 
GPR17+-cell population during disease induction and at distinct time-points after the 
disease onset. 
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Regarding the point aim to unveil the mechanisms that could modulate GPR17 expression 
during oligodendrogenesis, for this thesis project, we focused on the effects of 
“inflammatory” stimuli. 
It is known that cellular interactions between pro-inflammatory immune cells and CNS-
resident cell promote CNS tissue injury. In contrast, “anti-inflammatory” immune 
cells/molecules can positively influence CNS-resident cells promoting tissue repair and/or 
neuroprotection (Bennet J.L., et al., 2009).  
To get insight on the effects of immune cells and the other CNS cells on OPC differentiation 
and GPR17 expression we performed in vitro experiments, by exposing OPCs to either 
medium conditioned by reactive astrocytes or to different cocktails of cytokines typically 
released by polarized T-cells. Moreover, in light to the recent findings that GPR17 
promiscuously bind CXCL12, we also evaluated if this chemokine, already demonstrated to 
have a pro-differentiating effect on OPCs, could exert its function, not only via its known 
receptor CXCR4, but also through a direct interaction with GPR17. 
Finally, since there are no histological studies describing the pattern of GPR17+-cells in 
human MS lesion, we studied the expression profile of GPR17 in human cerebral tissues 
from MS patients in respect to the lesion type. GPR17 characterization in human samples is 
important for future development of drugs against this target. Indeed, in our laboratory we 
are now testing new compounds, modulating GPR17, in the EAE model (according to the 
aim “Testing new pharmacological/biotechnological strategies to correct GPR17 
dysfunction in MS and resume myelination”). The results of these experiments are not 
shown in this thesis because they are still ongoing. 
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Chapter	5	
Materials	and	methods	
 
5.1	EAE	experiment	
	
5.1.1	EAE	induction		
EAE was induced in 8-week-old female wild-type C57Bl/6 mice (Charles River) by 
subcutaneous immunization in the flanks and in the tail base with 200µg of myelin 
oligodendrocyte glycoprotein (MOG35-55, Espikem) per mouse in IFA (Sigma Aldrich) 
supplemented with 8 mg/ml of Mycobacterium tuberculosis (strain H37Ra, Difco). Mice 
immunized received 500 ng of pertussis toxin (PTX, Duotech) intravenously the day of the 
immunization and 48 h later. Animals were daily weighted and scored for clinical symptoms 
of EAE according the following scale: 0 = healthy, 1 = flaccid tail, 2 = ataxia and/or paresis 
of hindlimbs, 3 = paralysis of hindlimbs and/or paresis of forelimbs, 4= tetraparalysis, 5 
=moribund or death. Non-EAE controls received PTX injections, as well as the initial 
injections of emulsion but without the encephalitogen, to ensure that observed effects are 
due to EAE and not to a non-specific reaction to the ancillary components that are used to 
facilitate disease induction. Animals were sacrificed 21 days post immunization (dpi) for 
histological and real-time PCR analysis. 
5.1.2	EAE	in	transgenic	mice		
EAE was induced also in female adult mice (2- to 3-month-old) of the GPR17- 
iCreERT2xCAG-eGFP mouse line. Tamoxifen (40 mg/mL; Sigma Aldrich) was diluted in 
ethanol (final concentration 10%) and corn oil. Mice received for three times (every second 
day) 10 mg tamoxifen suspension by gavaging (for a total of 30 mg) 2 weeks before EAE 
induction and were sacrificed 21 dpi for histological and real-time PCR analysis.  
5.1.3	Histology	and	immunofluorescence		
	
Mice were anesthetized with chloral hydrate (400 mg/kg, Sigma Aldrich) and 
perfused transcardially with saline-0,1M EDTA (Sigma Aldrich) followed by 4% neutral 
buffered formalin (Sigma Aldrich) in deionized water. Spinal cords were collected and post-
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fixed for 1h in the same solution at 4 °C, cryoprotected in 30% sucrose for 24h (until the 
tissue sinks to the bottom of the tube), embedded in OCT and then frozen at –80°C. Spinal 
cords were cut transversally into 20um-thick sections with a cryostat and processed for 
immunofluorescence. 
Slides were incubated for 45 minutes at room temperature with a blocking solution 
composed by 10% normal goat serum and 0.1% triton-x 100 in PBS1x. 
Then, the sections were incubated with primary antibodies (see table 5.1) overnight at 4°C 
in PBS1x with 5% goat normal serum and 0.1% Triton-X 100. The next day, the sections were 
exposed for 1 h at room temperature to secondary antibodies and Hoechst33528 was used 
to visualize cell nuclei. After processing, sections were mounted on microscope slides with 
fluorescent mounting medium (Dako). 
GPR17 labeling was amplified with the high sensitivity tyramide signal amplification kit 
(Perkin Elmer) according to the manufacturer’s instruction.  
Name	 Company	 Dilution	
GPR17	 Home-made	 1:10,000	
Olig2	 Millipore	 1:500	
NG2	 Millipore	 1:200	
CC1	 Calbiochem	 1:50	
GSTp	 MBL	 1:500	
GFAP	 Cell	Signalling	technology	 1:500	
NeuN	 Millipore	 1:50	
Iba1	 Wako	 1:1000	
GFP	 Aves	Labs	 1:1400	
Table	5.1	–	List	of	all	the	primary	antibodies	used	to	perform	immunohistochemistry.	
5.1.4	In	situ	hybridization	
Slides were dried at RT for 5 minutes. After one wash in PBS1x-DEPC, slides were postfixed 
in 4% paraformaldehyde for 5 minutes, washed in PBS1x-DEPC, with SSC2x for 5 minutes 
each and then with Tris-Glycine 0.1M (pH7) for 20 minutes. Sections were permeabilzed in 
protease K (20 µg/ml) in PBS1x for 10 min at 37°C. The activity of protease K was stopped 
by fixation in 4% paraformaldehyde for 5 min, followed by 2x5 min washes in PBS1x to 
remove fixative from the sections. 
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Slides were incubated in 0.25% acetic diaminobenanhydride (Sigma-Aldrich) with 0.1 M 
triethanoloamine (pH 8.0) (Sigma-Aldrich) for 10 min at RT, followed by washing 2xSSC for 
10 min. Digoxigenin-labeled cRNA (0.3µg/ml) of either antisense or sense probes were 
added to hybridization buffer containing 50% formamide, 10% dextran sulphate, 1x 
Denhardt’s solution, 4xSSC, 250 µg/ml Salmon sperm, 10mM DTT and 250 µg/ml E. coli tRNA 
(RNase-free). Hybridization was carried out for 16 h at 55°C in a hybridization oven. The 
sections were washed in 2xSSC for 30 min at 52°C, 3x5min in 0.2xSSC at 52°C, 2x5min in 
2xSSC at 52°C and then let to cold in PBS1x at RT. The following protocol was used to 
detect the hybridization signals. Briefly, the sections were first incubated in the blocking 
buffer containing 3% bovine serum albumin (Sigma-Aldrich) and 0.1% Triton X-100 in PBS at 
RT for 30 min, and then with anti-digoxigenin sheep IgG Fab fragments conjugated to 
alkaline phosphatase (Roche Boehringer Mannheim) diluted 1:500 in the blocking buffer 
o/n. Slides were washed with PBS1x for 3x5 min, followed by washing in Buffer 1 (0.1M Tris-
HCl, pH 7.5, 0.1M NaCl), then equilibrated in Buffer 2 (0.1M Tris-HCl, pH 9.5, 0.1M NaCl, 
0.05M MgCl). The colour development was performed with 400µg/ml nitro blue tetrazolium, 
200µg/ml 5-bromo-4-chloro-3-indolyl phosphate and 100 µg/ml levamisole in buffer 2 in the 
dark at RT for 10 minutes. The sections were rinsed in distillate water to stop the colour 
development, then dried by soaking slides in successive baths of ethanol (50%, 75%, 95%, 
100%) and xylene for 10 minutes. Slide were mounted with DPX (Sigma-Aldrich).   
Mouse GPR17 cDNA sequences (sense: 5’ GATGAACGGTCTGGAGGCAGCC3’; antisense: 
5’CTCACAGCTCGGATCGGGCAC3’) were inserted into a T-vector (pBlu2KSM-T). Digoxeginin-
labeled RNA probes were synthesized following the manufacturer's instructions (Roche). 
5.1.5	Cell	counts	
After immunofluorescence, one section from each level (cervical, thoracic, and lumbar-
sacral) of the spinal cord was analysed for every animal. Seven arbitrary non-overlapping 
sample fields were counted separately in WM and six fields in GM of every section at 40x 
magnification (Fig. 5.1).  
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Figure	 5.1	 -	 Schematic	 representation	 of	 a	 spinal	 cord	 transversal	 section	 indicating	 the	 locations	 of	 the	 sample	 boxes	
(area=0.035	mm2)	used	for	cell	counts.	
	
5.2	In	vitro	experiments	
	
5.2.1	Primary	cultures,	OPCs	isolation	and	treatment	
Mixed glial cultures were obtained from 12 postnatal day 2 (P2) Sprague-Dawley rat 
cerebral cortices pooled together. The shaking protocol (Chen et al., 2007) allowed the 
sequential isolation of OPCs, astrocytes and microglia from the same preparation.  
OPCs were seeded onto 13 mm-glass coverlisps (15,000 cells/coverslip) coated with poly-
D,L-ornithine-coated (final concentration 50 µg/ml; Sigma-Aldrich) coverslips for 
immunocytochemistry and poly-D,L-ornithine-coated 12-wells plates (30,000 
cells/coverslip) for qRT-PCR assays. Cells were plated in Neurobasal medium supplemented 
with 2% B27 (Life Technologies), 2 mM L-glutamine, 10 ng/ml human platelet-derived 
growth factor BB (Sigma-Aldrich), and 10 ng/ml human basic fibroblast growth factor (Life 
Technologies) to promote proliferation (proliferating medium, PM). When OPCs reached a 
60% confluency, cultures were switched to a Neurobasal medium lacking growth factors and 
containing triiodothyronine 15 nM (T3, Sigma-Aldrich) to allow differentiation 
(differentiating medium, DF). 
To assay the effects of reactive astrocytes on oligodendrocyte differentiation, OPCs were 
incubated with supernatants derived from astrocytes activated by FBS starvation for 48 
hours, thereafter cells were fixed and stained. 
To determine the direct effects of cytokines on OPC differentiation, OPCs were treated for 
48 hours with two different cocktails of cytokines mainly released by Th1- Th2- polarized T 
cells:  TH1 (IL-1β,30ng/ml; IL-12,10ng/ml; CXCL12, 1.2nM; IL-17, 25ng/ml) and TH2 (IL-
4,10ng/ml; IL-6,10ng/ml; IL-10, 10ng/ml). Thereafter cells were fixed and stained. 
To determine the effects of CXCL12 on OPC differentiation, 24h after being in DM, OPCs 
were treated with human beta CXCL12 (1.2 nmol/l, Sigma-Aldrich) or vehicle for 48 hours 
and then fixed at room temperature (RT). Cells were pre-incubated for 30 min with the 
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antagonists cangrelor (10 nM/l, The Medicines Company, Parsippany, NJ) or AMD3100 (1 
µmol/l, Sigma-Aldrich), then treated with CXCL12.  
5.2.2	Astrocyte	culture	and	generation	of	astrocyte-conditioned	medium	
Astrocytes, obtained as described previously in 5.2.1., were plated in T75 flasks with DMEM 
containing 10% FBS (fetal bovine serum), penicillin/streptomycin, and glutamine. All cells 
were kept under sterile conditions in incubators at 37˚C. After 2 weeks, the medium was 
changed and replaced with a new one without FBS; astrocytes were cultured in this 
conditions for 10 days, after that the conditioned medium was collected, filtered and 
storage at -20°C.	 
5.2.2	Immunocytochemistry	and	cell	counting	 	
Cells were fixed in a 4% paraformaldehyde phosphate-buffered solution containing 4% 
sucrose. The following primary antibodies were used: rabbit anti-GPR17 (1:100; Cayman 
Chemical), rat anti-MBP (1:200; Merck Millipore). Incubation of primary antibodies were 
performed 2.5 hours at room temperature or over-night at 4°C. Cells were then incubated 
for 1 h at room temperature with secondary antibodies conjugated to either AlexaFluor 488 
or AlexaFluor 555 (1:600; Life Technologies). All the antibodies were diluted in a 
phosphate-buffered blocking solution (pH 7.4) containing 0.3% Triton X-100. Nuclei were 
labeled with the UV fluorescent dye Hoechst 33258 (1:10,000; Life Technologies). 
Coverslips were then mounted in a fluorescent mounting medium (Dako). Positive cells for 
the selected markers were counted from 20 random fields for each coverslip (0.07 
mm2/field).  
5.3	Total	RNA	extraction,	retrotranscription	and	gene	expression	analysis  
Total RNA was extracted from cells or tissues using Trizol reagent (Life Technologies).  
For gene expression analysis, cDNA synthesis was performed starting from 800 ng of total 
RNA using SuperScript® II Reverse Transcriptase (Life Technologies). The expression of all 
genes was analysed using Sybr-green reagents (Bio-rad) and normalized to GAPDH 
expression using CFX96 real time PCR system (Bio-rad) following the manufacturer’s 
protocol. The Ct values were elaborated with the Comparative CT method (ΔΔCT) which 
allows the relative quantification of template comparing the expression levels of the 
interested gene with the ones of the housekeeping gene. 
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5.4	Analysis	on	human	MS	tissue	
5.4.1	Tissue	Source	
The tissues supplied by the UK Multiple Sclerosis Tissue Bank at Imperial College, London, 
were collected postmortem with fully informed consent from both donors and close 
relatives. Procedures for retrieval, processing, and storage have gained ethical approval 
from all appropriate committees. The brain tissues analysed in this study were from 9 
neuropathologically confirmed cases of MS (see Table 5.2). Analysis was performed also on 
samples from patients who died due to non-neurological diseases. Cerebral hemispheres 
were fixed with 4% paraformaldehyde for about 2 weeks, coronally sliced, and blocked. 
Individual blocks were cryoprotected in 30% sucrose for 1 week and frozen by immersion in 
isopentane precooled on a bed of dry ice. Frozen tissue blocks were stored at –80°C. 
 
CASE	
AGE	
(YEARS)	
SEX	 DTPI	(h)	 DISEASE	COURSE	
DISEASE	
PHASE	
CLINICAL	DIAGNOSIS	
MS122	 44	 M	 16	 Secondary	progressive	 Progression.	 Chronic	multiple	sclerosis.	
MS200	 44	 F	 20	 Secondary	progressive.	 Stable.	 Chronic	multiple	sclerosis.	
MS234	 39	 F	 15	 Relapsing	progressive.	 Progression.	 Chronic	multiple	sclerosis.	
MS242	 57	 F	 12	 Secondary	progressive.	 Progressive.	 Chronic	multiple	sclerosis.	
MS297	 58	 F	 8	 Secondary	progressive.	 Progressive.	
Pathological	features	of	necrotising	
myelitis.	
MS300	 56	 F	 13	 Secondary	progressive.	 Progressive.	 Chronic	multiple	sclerosis.	
MS325	 51	 M	 13	 Primary	Progressive.	 Progressive.	 Chronic	multiple	sclerosis.	
MS317	 48	 F	 21	 Secondary	progressive.	 Progressive.	 Chronic	multiple	sclerosis.	
Table	5.2	–	Summary	of	patient	details	(DTPI,	death-tissue	preservation	interval)	
5.4.2	Lesion	Detection	and	Classification		
Cryostat sections (12 µm thick) were stained with Luxol fast blue, in order to detect WM 
lesions, or subjected to immunohistochemistry for MOG (1:200, Proteintech), in order to 
distinguish GM lesions. HLA (1:50, Dako) staining was performed to assess inflammation. 
Lesions were classified according to Van Der Valk and De Groot (2000).  
5.4.3	Immunohistochemistry	
After quenching endogenous peroxidase by a 10-min incubation with 1% H2O2 in methanol at 
-20°C, sections were incubated for 30 minutes in PBS 5% NGS at 4°C, with primary 
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antibodies as specified in 5.4.2 and in table 5.1. Sections were then incubated either with 
biotinylated secondary antibodies, followed by avidin-biotin-peroxidase reactions 
(Vectastain, ABC kit, Vector), using 3,3#-diaminobenzidine (Sigma-Aldrich) as a chromogen, 
or with fluorescent secondary antibodies (for immunofluorescence, as described in 5.1.3). 
The sections were rinsed in distillate water to stop the colour development, then dried by 
soaking slides in successive baths of ethanol (50%, 75%, 95%, 100%) and xylene for 2 minutes 
each. Slides were mounted with DPX (Sigma-Aldrich).  
5.5	Statistical	analysis	 	
Data are presented as mean ± standard error (SEM) of replicates. GraphPad Prism 6.0 was 
used for statistical analysis. For all comparisons between two groups with a normal 
distribution, two-tailed unpaired t-test was performed. For multiple comparison testing, 
one-way analysis of variance (ANOVA) accompanied by Dunnett’s post-hoc test was used. P 
values < 0.05 were considered statistically significant. 
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Chapter	6	
Results		
	
6.1	In	mouse	spinal	cord,	GPR17	is	expressed	in	cells	of	the	oligodendroglial	lineage	
As a first step, we characterized the expression pattern of GPR17 in control mouse spinal 
cord. The GPR17 receptor protein was present in a relatively high number of cells 
throughout the whole spinal cord of adult mice (Fig. 6.1A), where it clearly decorates 
oligodendroglial cells, as demonstrated by co-localization with the typical oligodendroglial 
transcription factor Olig2 (Fig. 6.1 panel B, B’). In particular, it is expressed in early OPCs 
with a bipolar phenotype positive for NG2, but also in maturing oligodendrocyte precursors 
positive for CC1 (Fig. 6.1 panel C, D). No co-localization was found with the astroglial or 
microglial markers like GFAP and Iba1 and the neuronal marker MAP2 (Fig. 6.1 E-G). Thus, 
we confirmed that also in spinal cord, as previously shown for brain (Lecca et al., 2008; 
Boda et al., 2011; Ceruti et al., 2011), GPR17 is specifically expressed in a subset of 
oligodendrocyte precursors at an intermediate stage of differentiation. 
6.2	Characterization	of	GPR17	expressing	cells	in	EAE	
The mRNA of GPR17 was previously found to be up-regulated in EAE, but the expression of 
the receptor protein was not investigated in detail. For this reason, we induced EAE, 
followed disease development for 21 days, sacrificed mice during disease acute phase, 
explanted the spinal cord and analysed GPR17 expression by qPCR and, in parallel, by 
immunohistochemistry.  
As shown in Fig. 6.2 A, the disease evolved as expected with the first clinical symptoms 
appearing around day 10 after MOG immunization, followed by a strong and progressive 
neurological impairment peaking between day 16 and 21. 
Real-time PCR analysis showed that GPR17 expression was almost doubled in EAE spinal 
cord compared to controls (Fig. 6.2 B), along with two inflammatory cytokines (i.e. IL-1β 
and TGF-β), that confirmed the presence of strong and acute inflammation (Fig. 6.2 C). The 
presence of increased receptor gene expression was also found by in situ hybridization 
showing GPR17-expressing cells accumulating at the borders of infiltration sites, where a 
large amount of blood borne cells are typically found (see Fig. 6.2 panel D). Accordingly, 
immunofluorescence analysis revealed GPR17-expressing cells accumulating at the lesions, 
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where both demyelination and inflammatory foci with infiltrating cells were found (Fig. 6.2 
panel E).  
In order to characterize whether the detected gene expression changes reflected 
alterations in the subpopulation of GPR17-positive oligodendrocytes, we evaluated by 
immunohistochemistry their co-localization rate with both NG2, a marker of early OPCs, 
and CC1, a marker of maturing oligodendrocytes. In line with the expected loss of 
oligodendrocytes in EAE, we found a reduction in the total number of GPR17+ cells in WM, 
but, despite this trend, the number of GPR17+NG2+ double-positive cells was increased (Fig. 
6.2 panel F), whereas no changes in the number of GPR17+CC1+ cells were found (Fig. 6.2 
panel G). These data suggest that the up-regulation of GPR17 gene expression reflects the 
expansion of the early proliferating cells responding to the lesion and still expressing the 
receptor, whereas more mature cells do not react.  
 
	
Figure	6.1	 -	Confocal	 images	of	 control	mice	 spinal	 cord	 immunolabeled	 for	GPR17	and	other	markers.	 (A)	Distribution	of	
GPR17+-cells	(in	red)	in	the	spinal	cord	of	an	adult	mouse.	Cell	nuclei	are	labelled	with	Hoechst	33258	(in	blue).	GPR17+-cells	
express	the	oligodendroglial	marker	Olig2	(B	and	inset	B’).	GPR17	presence	was	detected	in	cells	showing	co-localization	of	
both	the	early	OPC	marker	NG2	(C)	and	the	more	mature	marker	CC1	(D).	No	GPR17	positivity	was	found	in	microglia	(Iba1),	
neurons	(MAP2)	and	astrocytes	(GFAP)	(E,	F,	G).	Images	were	taken	at	the	confocal	microscope	(Zeiss	LSM	510	Meta).	Scale	
bars:	200µm	(A),	50µm	(B-G),	5µm	(B’).	
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Figure	6.2	-	Changes	of	GPR17	expression	after	acute	EAE	and	alterations	in	the	proportion	of	GPR17+	oligodendrocytes	pool	
in	 spinal	 cord	 of	 EAE	mice.	 Animals	were	 analyzed	 on	 day	 21	 after	 immunization	 (acute	 EAE).	 The	 graph	 in	 A	 shows	 the	
clinical	scores	of	mice	during	acute	EAE	±	SEM.	By	means	of	real-time	PCR,	a	significant	up-regulation	of	GPR17	was	found	in	
spinal	 cord	 of	 mice	 after	 acute	 EAE,	 compared	 to	 controls	 (B)	 and	 this	 correlated	 with	 the	 increased	 expression	 of	
inflammatory	cytokines	(C).	Histograms	show	the	fold	change	value	±	SEM	compared	to	control	set	to	1.	Two-tailed	Mann-
Whitney	t-student	test,	*	p≤0.05,	**	p<	0.01	from	3	independent	experiments.	GPR17	up-regulation	was	also	confirmed	by	
means	of	in	situ	hybridization	at	the	lesion	site	(blue	arrows	indicate	cells	with	increased	levels	of	GPR17	mRNA	(D).	Scale	bar	
100μm.	 A	 local	 up-regulation	 of	 GPR17+	 cells	 (white	 arrows)	 was	 observed	 after	 EAE	 induction	 in	 the	 same	 area	 where	
inflammatory	 cells	 infiltrate	 the	 tissue	 (characterized	 by	 a	 high	 number	 of	 nuclei,	 in	 blue),	 bordered	 by	 Iba1+	 activated	
microglial	cells	(E).	Scale	bar	50μm.		Proportion	of	GPR17+-NG2+	and	GPR17+-CC1+	double-positive	cells	 in	white	matter	(F,	
G).	Data	are	 the	mean±SEM	of	cervical,	 thoracic	and	 lumbar	sections;	CTL	n=3,	EAE	n=5).	Unpaired	two-tailed	Student’s	 t	
test;	**,	p<	0.01;	***,	p<	0.001;	###,	p<	0.001	compared	to	control	from	2	independent	experiments.		
6.3	Identification	and	fate	of	GPR17-expressing	cells	in	inducible	GFP-reporter	mice		
GPR17 typically decorates the 30-40% of OPCs (Boda et al., 2011; Viganò et al., 2015). We 
thus wondered whether this subset of GPR17+ OPCs could be differentially recruited after 
damage compared to OPCs that do not express GPR17, and if they were able to undergo 
terminal differentiation at inflammatory sites during EAE. 
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To do so, we took advantage of the transgenic inducible reporter mouse line 
GPR17iCreERT2:GFP (Fig. 6.3 panel A), in which, thanks to the activity of a Cre 
recombinase, upon tamoxifen administration, cells expressing GPR17 and their progeny are 
permanently labeled by the green fluorescent protein GFP (Viganò et al., 2015), thus 
allowing us to trace their destiny throughout animal’s life.  
First, to confirm successful transgene recombination and the identity of the recombined 
cells, we analyzed spinal cord sections in healthy mice. Importantly, we observed that 
virtually all the recombinant GFP+ cells remained within the oligodendrocyte lineage as 
nearly all of them were Olig2+ (Fig. 6.3 B-C). Many GFP+ cells were also positive for GPR17 
(Fig. 6.3 panel D) and the NG2 marker (Fig. 6.3 panel E). Although they were not abundant, 
we also detected several GFP+/GSTp+ cells (Fig. 6.3 panel F), suggesting that the increase 
in the number of GFP+-cells, observed in EAE, does not lead to augmented proportion of 
mature OLs. Vice versa, no co-localization of GFP+ cells was found with markers of 
microglia, neurons, astrocytes (Iba1, NeuN and GFAP, respectively) (Fig. 6.3 G-I). 
Then, to determine the fate of GFP+ cells following EAE, we used the same protocol 
described above, after tamoxifen-induced recombination. To avoid any pharmacological 
interference with the onset of the disease, tamoxifen was administered to adult 
GPR17iCreERT2:GFP transgenic mice 2 weeks before EAE induction (Fig. 6.4 panel A). After 
immunofluorescence, spinal cord sections were analyzed by counting cells at day 21 after 
immunization, when most animals reached the highest clinical score and clearly showed 
locomotor symptoms (Fig. 6.4 panel B). Interestingly, we observed a 3-fold increase in the 
number of GFP+ cells in WM, in particular in the regions of infiltration (Fig. 6.4 C-E), 
suggesting that cells expressing GPR17 responded to the insult with increased proliferation. 
Fate mapping analysis showed that most of the GFP+ cells were positive for NG2 (Fig. 6.4 F-
H), suggesting that these cells are specifically proliferating in the lesion area. Although we 
found some differentiated GFP+ cells expressing the mature marker GSTp in EAE mice, the 
number of these cells was not changed compared to control mice (Fig. 6.4 I-K), suggesting 
that their differentiative abilities are impaired, likely due either to demyelination itself, or 
to unfavourable local inflammatory environment. Globally these data suggest that the 
population of GFP+ cells is reacting mostly by expanding the pool of precursors, and that 
this is not followed by the maturation of these cells, at least at this disease stage. 
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Figure	 6.3	 -	 Identity	 of	 recombinant	 cells	 in	 the	 adult	 spinal	 cord.	 Schematic	 representation	 of	 the	 transgenic	 alleles	 in	
GPR17-iCreERT2:CAG-GFP	mice	 showing	 tamoxifen-responsive	 recombination	 of	 the	 CAG-GFP	 allele	 to	 induce	GFP	 in	 cells	
expressing	GPR17	(A).	Quantification	of	Olig2+	cells	among	GFP+	cells	 in	the	spinal	cord	reveals	that	nearly	all	 recombined	
cells	 belong	 to	 the	 oligodendroglial	 lineage	 (B,	 C).	Many	GFP+	 cells	were	 also	 found	 positive	 for	 GPR17	 (D)	 and	 the	NG2	
marker	(E).	Although	they	were	not	abundant,	we	detect	the	presence	of	some	GFP+-GST+	cells	(F).	Vice	versa,	GFP+	cells	are	
not	positive	 for	 the	markers	of	microglia,	 Iba1	 (G),	neurons,	NeuN	(G)	and	astrocytes,	GFAP	(I).	 Images	were	taken	at	 the	
confocal	microscope	(Zeiss	LSM	510	Meta).	Scale	bar:	10µm	(C,	F),	5µm	(C’),	50µm	(D-I).	
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	Figure	6.4	-	Reaction	and	fate	of	recombined	cells	in	the	spinal	cord	of	GPR17-iCreERT2	mice	after	acute	EAE.	Mice	received	
tamoxifen	by	oral	gavage	 three	 times	 (once	a	day	every	 second	day	 for	3	d),	 starting	14	d	before	EAE	 induction.	Animals	
were	analyzed	on	day	21	after	immunization	(A).	Clinical	scores	of	mice	during	acute	EAE.	Results	represent	mean	CS±	SEM	
of	15	EAE	mice	(B).	Representative	images	showing	fasciculus	gracilis	(FG)	of	spinal	cords	of	control	and	EAE	mice.	GFP+-cells	
are	visible	under	both	conditions	but,	after	EAE,	their	number	significantly	increased	in	the	infiltration	areas,	where	a	lot	of	
inflammatory	 cells	 were	 found	 (high	 number	 of	 nuclei,	 in	 blue,	 *)	 (C).	 Images	 were	 taken	 at	 20X	 magnification	 and	
reconstructed.	Quantification	of	the	number	of	GFP+-cells	in	EAE	spinal	cord	(D).	In	H	and	K,	characterization	of	the	identity	
of	 the	 GFP+	 cells	 in	 the	 white	matter	 spinal	 cord	 of	 GPR17-iCreERT2	mice	 after	 EAE.	 Data	 are	 the	mean±SEM	 of	 lumbar	
sections;	 CTL	 n=2,	 EAE	 n=5).	 Unpaired	 two-tailed	 Student’s	 t	 test,	 *	 p<	 0.05,	 ***	 p<	 0.001	 compared	 to	 control.	
Representative	images	showing	of	spinal	cords	of	control	and	EAE	mice.	Scale	bars:	100µm	(C,	D,	F,	G,	I,	J).	
6.4	 In	 the	 cuprizone-induced	 demyelination	 model	 GPR17	 kinetics	 correlate	 with	 MBP	
expression	pattern	
Next, we wondered if the local up-regulation of GPR17 at the lesion site was due to the 
inflammatory/immune response, or it was a specific feature of the demyelinating 
component of the disease. To address this issue, we took advantage of the cuprizone 
animal model, a highly reproducible system of primary OL apoptosis and secondary 
demyelination, which is characterized by much lower inflammation, and in which adaptive 
immune responses are not involved (Gudi et al., 2014). Wild-type mice received a 
cuprizone-supplemented diet for 5 weeks to cause demyelination and then switched to 
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normal diet up to 3 weeks to allow spontaneous re-myelination. As expected, the 
expression of MBP during the various disease stages followed a typical pattern (Tagge et al., 
2016), with a strong down-regulation starting from the first week of treatment and a 
gradual increase during the re-myelination phase, reaching higher levels at weeks 7 and 8 
(Fig. 6.5 panel A). Interestingly, also Gpr17 expression was significantly reduced in the 
early phases of demyelination and was then progressively restored to basal levels at the 
onset of the re-myelination phase, with no significant up-regulation compared to control 
mice and compared to the EAE model (Fig. 6.5 panel B). 
We conclude that, at variance from the EAE model (see above), after toxic cuprizone-
induced demyelination, there is no up-regulation of GPR17 levels. GPR17 changes during 
disease course instead follow the kinetics of other myelin genes. 
We thus suggest that, in a more complex disease like EAE, further components, such as the 
adaptive immune system or inflammatory factors released by immune cells, are present at 
lesion sites and may be responsible for the detected up-regulation of Gpr17 expression 
levels under these conditions.  
	
Figure	 6.5	 -	 Correlation	 of	 GPR17	 expression	 with	 progression	 of	 re-myelination	 in	 the	 cuprizone-induced	 demyelinating	
model.	GPR17	expression	detected	by	qRT-PCR	using	corpus	callosum	tissue	from	cuprizone	treated	wild-type	animals	(n=5)	
during	1,	2,	3,	4,	5	weeks	of	cuprizone	treatment,	and	after	animals	were	fed	with	standard	diet	for	one	(W6),	two	(W7)	and	
three	weeks	(W8).	
6.5	In	vitro	exposure	of	OPCs	to	medium	conditioned	by	activated	astrocytes	results	in	strong	
GPR17	stimulation	and	OPC	maturation	
To shed light on the mechanisms responsible for OPC activation after injury and to assess, 
in particular, the role of GPR17 in this activation, we focus our attention on astrocytes, 
another type of glia known to become “reactive” after damage (Kuhlmann et al., 2008). 
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Reactive astrogliosis is highly prevalent in inflammatory lesions and indeed represent one of 
the major pathological features of MS. Moreover, reactive astrocytes are known to release a 
variety of pro-inflammatory molecules, including cytokines, that could then play a role in 
GPR17 activation. 
To investigate how astrocytes can directly impact on OPCs differentiation and GPR17 
expression through the release of soluble products, rat primary OPCs were cultured with 
conditioned medium obtained from rat primary astrocytes activated by FBS starvation. 
After a 48h-exposure to astrocyte conditioned medium (ACM), we observed a strong positive 
effect on OPCs differentiation; in particular, the number of both GPR17+ and MBP+ cells was 
increased with respect to control condition (Fig. 6 panel A and B). Real-time PCR performed 
under the same conditions also confirmed up-regulation, with a 2-fold increase of GPR17 
gene expression and an almost 10-fold increase of MBP expression by real-time PCR (Fig. 6 
panel F). These data suggest that, as expected, astrocytes reacting to damage release 
soluble factors (including cytokines) that can then impact on OPC maturation. They also 
show that this likely occurs via GPR17 induction. 
6.6	In	vitro	exposure	of	OPCs	to	cytokines		
As	 a	 following	 step, we investigated the direct effect of cytokines typically released at 
inflammatory sites (both in EAE and MS lesions) on the expression of Gpr17. In attempt to 
model the contribution, to OPC differentiation, of typical cytokines released by both 
astrocytes and cells of adaptive immune system, primary rat OPCs were cultured with two 
different cocktails of cytokines mainly released by Th1- Th2- polarized T cells:  TH1 (IL-1β, 
IL-12, CXCL12, IL-17) and TH2 (IL-4, IL-6, IL-10) (Zeis et al., 2015). Cells were treated with 
TH1 and TH2 cocktails for 48h and were then fixed and stained to determine GPR17 and 
MBP. After exposure to TH1 cytokines, we observed an increase only in the number of 
GPR17+ cells, without any pro-differentiating effect with respect to control (Fig. 6.6, panels 
C and E); instead, after exposure to TH2 cytokines, we observed an increase in the number 
of GPR17+ cells associated with an increase in the number of MBP+ mature OLs (Fig. 6.6 
panels D and E). Real-time PCR revealed that TH1 cytokines induced a 2-fold increase of 
GPR17 expression that was not accompanied by an increase of MBP levels. No significant 
effects on GPR17 and MBP expression levels was observed after TH2 exposure (Fig. 6.6 
panel F).  
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All together, these results suggest that impaired OPC maturation observed after the 
treatment with pro-inflammatory cytokines could be due to at least in part to GPR17 
sustained up-regulation. 
6.7	GPR17	is	a	promiscuous	receptor	that	can	be	also	activated	by	CXCL12		
As already mentioned, after CNS injury, astrocytes secrete a variety of factors (including 
cytokines and chemokines like CXCL12) that can influence OPC survival, migration, 
differentiation, and subsequent myelination (Moore et al., 2011). This confirms that 
astrocytes can be considered important regulators of myelination and re-myelination in the 
CNS. Recently, we reported a promiscuous behavior for GPR17 and demonstrated that this 
receptor can indeed also bind to the chemokine CXCL12 (also known as SDF-1) both in silico 
and in vitro (Parravicini et al., 2016). Specifically, in primary OPC cultures, treatment with 
CXCL12 alone increases by approximately 30% the number of MBP-positive cells compared 
to control conditions, thus accelerating their differentiation toward a mature phenotype, in 
line with literature data (Li et al., 2012; Patel et al., 2010; Carbajal et al., 2010) (see Fig. 
6.7, panel A, B and E). As also shown in Fig. 6.7, this increase is not observed when CXCL12 
is added to cells either in combination with the GPR17 antagonist Cangrelor (panel C, E), 
or, as expected, with the CXCR4 antagonist Plerixafor (panel D, E). In both antagonist 
groups, the number of MBP-positive cells is comparable to, or slightly lower than, the one 
measured in the vehicle-treated cells. 
Globally, these results demonstrate that CXCL12, at a concentration able to activate its 
cognate receptor CXCR4, can also directly act as a promiscuous activator of GPR17, 
corroborating our hypothesis of a common pathophysiological role for GPR17 and chemokine 
receptors in leading the re-myelination processes.  
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Figure	6.6	-	Effects	of	reactive	astrocyte	conditioned	medium	and	TH1-	and	TH2-	cytokine	cocktails	on	GPR17expression	and	
OPC	 differentiation.	 Representative	 images	 of	 GPR17-	 (in	 red)	 and	MBP-expressing	 cells	 (in	 green)	 treated	 for	 48h	 with:	
vehicle	(A)	reactive	astrocyte	conditioned	medium	(ACM)	(B),	TH1	cytokine	cocktail	(IL-1b,	IL-12,	CXCL12,	IL-17)	(C)	and	TH2	
cocktail	(IL-4,	IL-6,	IL-10)	(D).	Cell	nuclei	are	labelled	with	Hoechst	33258	(in	blue).	Exposure	to	ACM	of	rat	OPCs	increase	the	
number	 of	 cells	 expressing	 both	 GPR17+-OPCs	 and	 MBP+-oligodendrocytes	 after	 48	 hours	 (B,	 E).	 Histograms	 show	
quantification	of	the	percentage	of	GPR17-	and	MBP	positive	cells	after	48	h	of	treatment	with	vehicle	and	with	ACM,	TH1	
and	TH2	cytokines	cocktails.	The	number	of	positive	cells	was	counted	in	20	optical	fields	under	a	40×	magnification.	Data	
are	 the	 mean	 ±	 SEM;	 from	 2	 independent	 experiments;	 one-way	 ANOVA	 Dunnett	 multiple-comparisons	 test	 **p<0.01,	
compared	to	control.	In	F,	histograms	show	quantification	of	Gpr17	and	Mbp	gene	expression	levels	by	real-time	PCR	after	
48	 h	 of	 treatment	 with	 vehicle	 and	 with	 ACM,	 TH1	 and	 TH2	 cytokines	 cocktails.	 Data	 are	 the	 mean	 ±	 SEM;	 from	 2	
independent	 experiments;	 one-way	 ANOVA	 Dunnett	 multiple-comparisons	 test**p<0.01,	 ****p<0.01	 compared	 to	
control=1.		
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Figure	6.7	–	CXCL12-mediated	activation	of	GPR17	in	OPCs.	Representative	images	of	MBP	expressing	cells	(in	red)	treated	
with	vehicle	(A)	and	CXCL12	(also	known	as	SDF-1)	alone	(B),	or	in	combination	with	the	GPR17	antagonist	cangrelor	(C)	and	
with	 the	 CXCR4	 antagonist	 Plerixafor	 (D).	 Cell	 nuclei	 are	 labelled	 with	 Hoechst	 33258	 (in	 blue).	 (E)	 Histograms	 show	
quantification	of	the	percentage	of	MBP	positive	cells	after	48	h	of	treatment	with	vehicle	and	with	CXCL12	alone	(CXCL12-
treated	cells	set	to	100%),	or	in	combination	with	cangrelor	(C)	and	plerixafor	(P).	The	number	of	positive	cells	was	counted	
in	 20	 optical	 fields	 under	 a	 40×	magnification.	 Data	 are	 the	mean	 ±	 SEM	 of	 at	 least	 three	 independent	 experiments.	 *,	
p<0.05;	**,	p<0.01	compared	to	CXCL12	treated	cells;	one-way	ANOVA	Dunnett's	Multiple	Comparison	Test.	Scale	bar:	50	
μm.	
6.8	GPR17	is	pathologically	up-regulated	in	demyelinating	lesions	of	human	MS	subjects	
Finally, we wondered whether GPR17 up-regulation was also associated with human MS 
demyelinating lesions like in EAE. To answer this question, we first analysed the presence 
of GPR17 in human cortex from autoptic specimens of control subjects died for non-
neurological diseases (data not shown), and then we compared these data with GPR17 
expression in a cohort of MS patients (see table 5.2). 
As previously observed in mouse, GPR17+ cells were homogeneously distributed throughout 
the normal appearing white matter (NAWM) (Fig. 8 panel A), co-expressing the marker 
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Olig2, confirming an abundant expression of the receptor also in human cells belonging to 
the oligodendroglial lineage (Fig. 8 panel B).  
In the pathological specimens from MS patients, as observed in EAE, many GPR17+ cells 
were found at the border of active demyelinating MS lesions (Fig.8 panel C) also identified 
by means of the luxol-fast blue staining (Fig.8 panel D). However, at variance with the 
rodent tissues, these cells showed a completely different morphology, resembling that of 
reactive astrocytes (Fig.8 panel E). GPR17 clearly co-localized with both the human 
leukocyte antigen (HLA), which is typical of antigen presenting cells, microglia and 
astrocytes, and the markers Iba1 and GFAP (Fig.8 F). These data suggest that, in human 
cortex, GPR17 decorates different types of cells activated or recruited at the border of 
active MS lesion sites.  
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Figure	6.8	 -	 Sections	 from	autopsy	 frontal	 cortex	of	human	MS	patients.	GPR17	 is	present	on	oligodendrocytes	 in	normal	
appearing	white	matter	 (NAWM)	 (A).	 Hoechst	 (blue)	 stains	 nuclei.	 Double	 immunofluorescence	 staining	with	 GPR17	 and	
Olig2	(B).		In	C,	images	of	an	active	lesion	(AL;	demarcated	with	dashed	lines)	taken	at	10X	magnification	and	reconstructed.	
In	this	region,	where	demyelination	occurs	as	shown	by	luxol	fast	blue/Hematossilin	staining	(LFB/H;	panel	D),	many	GPR17+	
cells	 accumulate	 at	 the	 border	 but	 they	 have	 a	 different	 morphology	 compared	 to	 those	 in	 NAWM	 (E)	 and	 are	
GPR17+HLA+Iba1+(F).		Scale	bar:	50μm	(B,	E,	F)	100μm	(A);	200μm	(C).			
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Chapter	7	
Discussion	
	
In recent years, GPR17 has emerged as an important key actor in oligodendrogenesis. 
Previous studies have shown that, in the brain, GPR17 indeed acts as an intrinsic regulator 
of this process, it is needed to start OPC differentiation but at a certain stage of 
differentiation, it has to be turned down to allow the terminal maturation of immature 
oligodendrocytes (Fumagalli et al., 2015). Here, we provide for the first time the 
characterization of GPR17 in the spinal cord and analyse its changes after induction of EAE 
in rodents. We also provide the first analysis of GPR17 in the CNS plaques of MS patients. 
GPR17-positive OPCs react to EAE induction  
The rodent studies have suggested that, under physiological conditions, GPR17 has a 
widespread expression on the OPCs in both brain and spinal cord, suggesting a role in the 
normal homeostasis and in the turnover of oligodendrocytes. Here, we confirm that GPR17 
expressing cells are widespread throughout the whole spinal cord, both in grey and white 
matter (Figure 6.1 A). It was also demonstrated that, at least in the brain, under normal 
conditions, cells expressing GPR17 are relatively quiescent and they proceed in the 
differentiating process only after 11 weeks. However, these cells can very rapidly react to 
insults, thus representing a pool of cells able to react to emergency situations (Viganò et 
al., 2015). Thus, it seems that the presence of the receptor enables OPCs and immature 
oligodendrocytes to react to injury through its activation, which is also in line with our 
previous data suggesting GPR17 as a “sensor of damage” (Lecca et al., 2008; Ceruti et al., 
2009; Buffo et al., 2011). Therefore, the presence of GPR17 in adult spinal cord 
parenchyma suggest that, in a similar way to the brain, also in this part of the CNS GPR17 
likely makes OPCs able to react to insults. These conclusions are also supported by the data 
obtained in the first inducible GPR17 GFP-fluorescent reporter mouse, in which successful 
tamoxifen-induced recombination took place in GFP+-OPCs and immature oligodendrocytes, 
confirming that, both in brain and spinal cord parenchymas, there is a subset of adult 
oligodendrocytes on which the promoter regulating GPR17 expression is active, even under 
physiological conditions. 
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Specifically, GPR17 expression pattern is significantly altered during EAE induction. As 
previously reported by Chen and colleagues (Chen et al., 2009), the mRNA for GPR17, in 
EAE mice, was found to be upregulated mostly at inflammatory areas showing infiltration of 
blood born cells, indicating that its expression is specifically induced in a subset of cells 
reacting to the insult. In a similar way to what already shown in the brain (Viganò et al., 
2015), these quiescent GFP+ cells are able to strongly enhance their proliferation rate in 
response to inflammation/demyelination. After acute EAE, we observed a 3-fold increase in 
the number of GFP+ cells in the areas characterized by infiltrating cells compared to 
controls. In particular, GFP+-NG2+ were very reactive in line with literature data showing 
that after injury OPCs actively proliferate to enhance the pool of progenitors in order to 
support the differentiation and maturation of some of them to substitute the injured ones. 
Previous time-lapse imaging has revealed how NG2+ cells are recruited to sites of focal CNS 
injury and rapidly migrate and proliferate to restore their density (Hughes et al., 2013). As 
already mentioned, in different mouse models of acute brain injury and ischemia, it has 
been recently demonstrated that GPR17+-NG2+ cells represent a rapidly reacting reserve 
pool (Viganò et al., 2015). Our data support a very similar behaviour of spinal cord OPCs 
after acute EAE, when GPR17+ cells undergo activation and proliferation in order to 
counteract the insult. In a recent interesting study, it was also demonstrated that activated 
OPCs show a neonatal-like transcriptome, enhanced differentiation and migration 
capabilities, in parallel to increased expression of several genes including chemokines (e.g. 
IL-1b, CCL2) and purinergic receptors (e.g. P2Y2R) (Moyon et al., 2015), providing further 
evidence that OPC population is heterogeneous and differentially reacts to insults and it is 
influenced by the environment. 
Here we report that the GPR17+-NG2+ subpopulation of cells in the WM reacts to the 
demyelinating insult by expanding their pool and also that this behaviour is restricted to 
the region where demyelination occurs, demonstrating that, also in the spinal cord, OPCs 
are not homogeneous. 
It is well established that, in the postnatal and adult brain, NG2-glia represent the largest 
population of endogenous/resident progenitor cells (4–8% of total cells, depending on the 
brain region), capable of rapidly “reacting” to any type of injury and with a strong 
potential to repopulate areas of lesion (Aguirre and Gallo, 2007; Filous et al., 2014; Scafidi 
et al., 2014; Simon et al., 2011). NG2-glia cells morphology and their functional properties 
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are distinct in different brain region and interactions between NG2-glia and other neural 
cell types may vary between brain areas. Fate-mapping studies showed region-dependent 
differences in NG2-glia differentiation: e.g. the majority of adult NG2-glia located in the 
WM of the cerebral cortex differentiate mostly into mature, myelinating oligodendrocytes, 
while GM NG2-glia generate fewer mature oligodendrocytes (Dimou and Gallo, 2015). 
Further studies are necessary to fully understand how distinct subpopulations of NG2-glia 
display differences in their properties and functions.  
In this respect, due to its “promiscuity” and ability to respond to different type of ligands 
accumulating at injury sites (Parravicini et al., 2016; Sensi et al., 2014), GPR17 could have 
a key role in “sensing” changes in the extracellular environment and contributing to the 
adaptive properties of the NG2-glia. 
GPR17 is a sensor of neuro-inflammatory damage 
At variance from the EAE model, in the cuprizone-induced demyelination model, that 
provides a highly reproducible system of primary OL apoptosis and secondary demyelination 
and where adaptive immune responses are not involved, we didn’t observe any Gpr17 up-
regulation. We instead found that Gpr17 expression levels, after their initial down-
regulation during the demyelination phase, are re-established to basal levels during re-
myelination and that these changes followed the kinetics of other myelin genes (Fig.6.5). 
We thus suggest that, in a more complex disease like EAE, further components, such as the 
adaptive immune system or inflammatory factors released by immune cells, are present at 
lesion sites and may be responsible for the detected up-regulation of Gpr17 expression 
levels under these conditions.  
The explanation of this behaviour could be linked to intrinsic GPR17 properties: GPR17 is 
indeed placed at an intermediate structural and phylogenetic position between already 
known P2Y and CysLT receptors and has been demonstrated to respond to UDP, UDP-glucose 
and UDP-galactose in the micromolar range (Benned-Jensen and Rosenkilde, 2010; Ciana et 
al., 2006; Daniele et al., 2014; Lecca et al., 2008) fully consistent with the concentrations 
at which these endogenous ligands activated their already known cognate P2Y receptors 
(Abbracchio et al., 2006). Interestingly, GPR17 is also activated by cysteinyl-leukotrienes 
(LTC4, LTD4 and LTE4), inflammatory mediators released upon damage (Ciana et al., 2006). 
More recently, GPR17 has been also reported to respond to emergency signals like 
oxysterols, or to cytokines, like CXCL12 (Parravicini et al., 2016), in a similar way to other 
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related receptors involved in inflammatory responses, like Epstein Barr virus induced gene 
receptor-2 and CXCR2 (Sensi et al., 2014). That is possible because GPR17 also shares some 
structural, phylogenetic and functional properties with some chemokine receptors (CXCRs), 
according to other recent data in literature that are challenging the currently accepted 
dogma that each receptor responds to a single endogenous ligand or a single family of 
related signalling molecules. Both GPR17 and CXCR2 are operated by oxysterols, and both 
GPR17 and CXCR ligands have been demonstrated to have a role in orchestrating 
inflammatory responses and OPC differentiation to myelinating cells in acute and chronic 
diseases of the CNS.  
Interestingly, in our in vitro experiments, although CXCL12 was present in the TH1 cocktail, 
we only reported an up-regulation of GPR17 without any effect on the proportion of 
maturing OLs. It might be that when CXCL12 is present at excessively high concentrations 
and in combination with other cytokines, like in EAE/MS lesions, it does not induce 
differentiation, but instead causes blockade of OPCs at immature stages. This hypothesis is 
in line with the present findings in the EAE model and with previous data in other neuro-
inflammatory conditions like brain trauma or ischemia (Boda et al., 2011; Lecca et al., 
2008; Ceruti et al., 2009) showing that when GPR17 is up-regulated on OPCs by high levels 
of “emergency signals” (e.g. CysLTs, oxysterols, CXCL12) cells are blocked at immature 
stages and do not proceed to terminal differentiation.  
Taken together, these findings support the emerging hypothesis that GPR17 may 
promiscuously respond to different signalling molecules depending on specific 
pathophysiological conditions and emergency situations. 
GPR17 responses may also vary depending upon its heterodimerization with other 
receptors, including P2Y and Cys-LT receptors (Maekawa et al., 2009), which could help 
explain why agonists at GPR17 have such diverse chemical structures. This also suggests 
that GPR17 may function as an adaptor protein for enhancing the agonist repertoire of 
other GPCRs, consistent with the conclusion that MDL29,951, an agonist of GPR17, can 
engage Gq as well as Gi proteins (Fumagalli et al., 2011; Hennen et al., 2013). 
The ability of GPR17 to respond to different classes of GPCR ligands suggests that this 
receptor modifies its function depending on the extracellular milieu changes occurring 
under specific pathophysiological conditions suggesting GPR17 as a strategic target for 
neurodegenerative diseases with an inflammatory/immune component. In this respect, 
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investigating GPR17 downstream will be interesting in order to describe “activated” OPC 
phenotype under pathological conditions like MS.  
This study could increase the knowledge of signalling mechanisms in resolution, opening 
new directions to treat inflammation-associated diseases, such as MS where the chronicity 
of inflammatory can be associated with inadequate engagement of resolving pathways by 
DMTs; this approach may lead to combined therapies that, on the one hand, control 
inflammation and neurodegeneration, and on the other hand, foster re-myelination. 
In human MS active lesions GPR17 is expressed by cells involved in inflammatory 
responses  
Dysregulated expression of GPR17 has been described also in human samples from patients 
with traumatic brain injury (Franke et al., 2013). In both neurosurgical and autopsy 
specimens, GPR17 expression was evident inside the contused core and progressively 
declined distally according to a spatio-temporal gradient. Inside and around the core, 
GPR17 labelled dying neurons, reactive astrocytes, and activated microglia/macrophages. 
In peri-contused   parenchyma, GPR17 decorated OPCs indicating re-myelination attempts.  
GPR17 was found overexpressed in MS plaques as compared with white matter from non-
neurological donor samples and normal-appearing white matter from MS donors (Chen et 
al., 2009), but the cellular distribution of the receptor was not investigated yet. Here we 
show that, indeed, in human brain GPR17 is expressed in oligodendroglial cells, but in 
active lesions it clearly decorates reactive microglia cells expressing HLA, and reactive 
astrocytes. These data suggest that in human MS, GPR17 is involved in reparative processes, 
exclusively at the lesion site, in a more complex fashion compared to that observed in 
rodents. Its expression in different cells suggests a cell type-specific expression and 
regulation of the receptor. In fact, it is known that, in humans GPR17 is physiologically 
present in OPCs and immature oligodendrocytes but the significance of its expression in 
other cell types is still elusive (Franke et al., 2013). Our hypothesis is that GPR17 could 
enable microglia and astrocytes to detect changes in their local environment and respond 
to release of inflammatory mediators within minutes. Our observations are related to active 
lesions but, in the next future, it will be interesting investigating whether GPR17 is involved 
in the evolution and in the progression of the MS lesions. 
It is worth to mention that although human GPR17 is highly similar to the rodent receptor, 
in humans, the receptor is also present in a longer isoform, bearing 28 additional amino-
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acids at the N-terminus (Pugliese et al., 2009). It has been previously demonstrated that 
both isoforms are functional when transfected in non-native systems, and even if they are 
both activated by the same ligands, their pharmacological profile and their signalling are 
different (Pugliese et al., 2009; Benned-Jensen and Rosenkilde 2010).  
It is possible that, during evolution, primates developed a longer isoform to introduce new 
variability in this gene enabling a differential expression of GPR17 in non-oligodendroglial 
cells, such as activated microglia and astrocytes.  
Our hypothesis is that GPR17 could be part of inflammation resolution process in the CNS. 
Its promiscuity and its cell-type specific expression including microglia and astrocytes, cells 
directly involved in the inflammatory reaction to the demyelinating insult, make this 
receptor a good candidate to shed light on molecular mechanisms occurring in the evolution 
of human MS plaques.  
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